ORIGINAL RESEARCH



Using network data envelopment analysis to assess the sustainability and resilience of healthcare supply chains in response to the COVID-19 pandemic

Majid Azadi¹ · Zohreh Moghaddas² · Reza Farzipoor Saen³ · Angappa Gunasekaran⁴ · Sachin Kumar Mangla⁵ · Alessio Ishizaka⁶

Accepted: 3 October 2022

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

The widespread outbreak of a new Coronavirus (COVID-19) strain has reminded the world of the destructive effects of pandemic and epidemic diseases. Pandemic outbreaks such as COVID-19 are considered a type of risk to supply chains (SCs) affecting SC performance. Healthcare SC performance can be assessed using advanced Management Science (MS) and Operations Research (OR) approaches to improve the efficiency of existing healthcare systems when confronted by pandemic outbreaks such as COVID-19 and Influenza. This paper intends to develop a novel network range directional measure (RDM) approach for evaluating the sustainability and resilience of healthcare SCs in response to the COVID-19 pandemic outbreak. First, we propose a non-radial network RDM method in the presence of negative data. Then, the model is extended to deal with the different types of data such as ratio, integer, undesirable, and zero in efficiency measurement of sustainable and resilient healthcare SCs. To mitigate conditions of uncertainty in performance evaluation results, we use chance-constrained programming (CCP) for the developed model. The proposed approach suggests how to improve the efficiency of healthcare SCs. We present a case study, along with managerial implications, demonstrating the applicability and usefulness of the proposed model. The results show how well our proposed model can assess the sustainability and resilience of healthcare supply chains in the presence of dissimilar types of data and how, under different conditions, the efficiency of decision-making units (DMUs) changes.

Keywords COVID-19 pandemic · Healthcare supply chains · Efficiency measurement · Sustainability and resilience · Network data envelopment analysis (NDEA)

1 Introduction

COVID-19 was first diagnosed in Wuhan, China, in December 2019 and then quickly spread throughout the world. The subsequent unique and unprecedented COVID-19 pandemic has

Published online: 21 October 2022

Extended author information available on the last page of the article



inflicted devastating damage on the world economy, people's health, jobs, and lives, and put the entire globe on hold for almost a year. According to official statistics, by April 2022, over 484 million COVID-19 cases and 6,152,000 deaths had been reported to World Health Organisation (WHO). Furthermore, the COVID-19 pandemic outbreak has negatively affected global economic growth. Estimations show that it could have reduced growth of the world's economy by 6.0% in 2020, despite partial improvement in 2021 and 2022, presuming no waves of reinfection. Due to the pandemic, the risks of a global economic slump are rising dramatically and unemployment has been rising at an unprecedented rate since the Great Depression of the 1930s. The human and economic costs such as death, poverty, and social unrest are only some examples of the devastation wrought by the COVID-19 pandemic.

One particularly affected area by the COVID-19 pandemic is supply chains (SCs). SCs are experiencing unparalleled vulnerabilities and disruptions (Zahedi et al., 2021). This type of pandemic can cause many parts of an SC to be inoperable and inefficient for an uncertain period (Govindan et al., 2020). The spread of the COVID-19 pandemic around the globe shows the importance and essential role of resilient SCs in supplying products and providing services to the world. The pandemic is testing the features of resilient SCs such as flexibility, robustness, and recovery (Elluru et al., 2019; Sharmin et al., 2021). Moreover, many organisations use the opportunity of this unprecedented crisis to adopt global SCs strategies and address sustainability in order to mitigate future challenges (Karmaker et al., 2020). Integrating sustainable and resilient concepts into SCs—including those of healthcare—is critical for organisations. Even so, the literature has not adequately addressed these concepts in healthcare SCs.

Efficiency assessment of healthcare SCs in the face of pandemic outbreaks, particularly COVID-19, can support healthcare systems to identify the existing inefficiencies. Disruptions in healthcare SCs, due to the surge of demand, can severely affect the performance of healthcare systems, leading to a substantial increase in the number of infected people and death. To mitigate the destructive impacts of COVID-19, different stages of healthcare SC such as suppliers, hospitals, and pharmacies need to act efficiently and resiliently. To benefit from an efficient healthcare system, each stage of healthcare SCs should use the available resources, reduce waste, provide timely services, and control process costs (Göleç & Karadeniz, 2020; Min et al., 2021). It should be noted that developing state-of-the-art performance evaluation approaches can assist healthcare managers to enhance the performance of healthcare systems in disaster management such as the COVID-19 epidemic (Md Hamzah et al., 2021).

Operating under uncertainty, resource scarcity, and demands surge are major issues for SCs in face of pandemic outbreaks. In this regard, Operations Research (OR) approaches and models are of huge importance (Besiou et al., 2018). Data envelopment analysis (DEA) derived from OR is a rigorous nonparametric approach to measure efficiency in many areas such as healthcare and humanitarian supply chains (Jola-Sanchez et al., 2016). DEA is the most accepted method to evaluate efficiency (Emrouznejad & Yang, 2018). Since the outbreak of COVID-19 in December 2019, the performance of healthcare SCs has been adversely affected. Under such turbulent circumstances, it is essential to develop and apply OR advanced methods such as network DEA to identify inefficiency sources and performance improvement in healthcare systems.

In this paper we deal with some research questions as follows: (1) how sustainability and resilience of healthcare supply chains can be evaluated in response to the COVID-19 pandemic outbreak? (2) how dissimilar types of data can be modeled in network structures? (3) to what extent sustainability and resilience of healthcare supply chains are changed under different conditions?



The main objective of this paper is to measure the sustainability and resilience of healthcare SCs in the face of the COVID-19 pandemic. Our proposed approach is built based on the range directional measure (RDM) model in the network DEA context. Furthermore, the developed model can deal with ratio data, integer data, stochastic data, negative data, undesirable data, and zero data. In sum, and to the best of our knowledge, this study makes the following contributions:

- To assess the sustainability and resilience of healthcare SCs, we propose a novel non-radial RDM network model.
- Our proposed approach can address different types of data such as ratio, integer, undesirable, stochastic, negative, and zero, simultaneously.
- Our proposed approach recommends how to improve the efficiency of healthcare SCs.
- We have validated this approach using a case study.

The rest of this paper is organised as follows. In Sect. 2, we provide the literature review. In Sect. 3, we present our approach, followed by the case study in Sect. 4. Finally, we conclude and propose possible future research in Sect. 5.

2 Literature review

2.1 Pandemic outbreaks and healthcare supply chains (SCs)

Healthcare SCs play a key role in providing required medical devices and services to people (Leite et al., 2020). After a pandemic disease, medical assistance is needed instantaneously (Verma & Gustafsson, 2020). The COVID-19 pandemic has adversely affected healthcare SCs. Pandemic diseases including COVID-19 and SARS are considered a specific type of risk to SCs. In epidemic outbreaks, efficient healthcare SCs can supply not only medical equipment but also mitigate disruptions (Rainisch et al., 2020). The outbreak of a pandemic disease quickly increases the demand for medical assistance (Dolinskaya et al., 2018). Healthcare SCs cannot be efficient when there is high uncertainty in demand (Hoyos et al., 2015). Moreover, due to the complexity of the structures of healthcare SCs, any unexpected event results in considerable changes to the services provided to patients (Md Hamzah et al., 2021). For example, inaccurate evaluations of needs can lead to shortages in crucial medical devices and services. However, efficient transportation systems in healthcare SCs improve inventory and capacity (Ruan, et al., 2014).

2.2 Efficiency measurement in healthcare SCs

The literature does address efficiency measurement somewhat in healthcare SCs. Chen et al. (2013) examined the effect of hospital–supplier incorporation on SC efficiency. Their study showed the effect of knowledge exchange, trust, and information technology (IT) integration on hospital SCs. Al-Saa'da et al. (2013) evaluated different aspects of SCs such as compatibility, relationship with suppliers, standards, requirements, and delivery of quality healthcare services. They demonstrated the important impact of these aspects on the quality of healthcare services. They also showed that there are no differences between SCM and the quality of health services owing to different factors. Nyaga et al. (2015) investigated the influence of internal and external factors on the performance of healthcare SCs. They used the data for more than 200 hospitals in the US over several consecutive years to estimate regression



models. They demonstrated that employing physicians and managing contracts improved the efficiency of healthcare SCs.

Supeekit et al. (2016) used the analytic network process (ANP) for evaluating the efficiency of hospital SCs. They examined the interdependencies between efficiency groups. They demonstrated that the completeness of treatment and processing times of clinical care is the most significant dimension of hospital SCs. Chorfi et al. (2019) presented a DEA model to measure the efficiency of healthcare SCs in the presence of interval data. To do so, first, they used the Latin hypercube sampling by replacement (LHSR) method for identifying a set of deterministic data from interval data; then they used DEA models to evaluate the efficiency of healthcare SCs. To evaluate the performance of sustainable healthcare SCs, Leksono et al. (2019) integrated a balanced scorecard (BSC), a decision-making trial, an evaluation laboratory (DEMATEL), and ANP techniques. They showed that the customer perspective is the most significant factor in the performance evaluation of healthcare SCs. Göleç and Karadeniz (2020) presented a fuzzy model to analyse the efficiency of healthcare SCs concerning competency-based operation assessment. They took the hierarchical structure of healthcare SCs such as processes and sub-processes into account in their proposed method. They also used two levels for evaluating processes and sub-processes. Gerami et al. (2020) presented a network DEA-R model to assess the performance of healthcare SCs. They modelled relations between the different layers of healthcare SCs based on network DEA and free-link and fixed-link assumptions. Md Hamzah et al. (2021) examined the performance of healthcare systems in Malaysia in the face of the COVID-19 epidemic. To address this issue, they applied a network DEA model using a secondary data. Md Hamzah et al.'s (2021) proposed network structure for evaluating the performance of the healthcare systems consisted of three stages. Min et al. (2021) sought to detect the sources of the success and failure of COVID-19 control measures and to enhance public health policies aimed at decreasing COVID-19 spread. They assessed the efficiency of different combinations of COVID-19 control measures and public health polices in OECD countries by focusing on the country-specific factors of government COVID-19 preventive measures in OECD countries. In doing so, they detected influential cultural variables. Although the above studies investigated performance evaluation of healthcare SCs from different perspectives, none of them evaluated the sustainability or resilience of healthcare SCs in response to a pandemic outbreak such as SARS and COVID-19.

2.3 Data envelopment analysis (DEA)

DEA has been recognised as the most rigorous and accepted method for measuring the relative efficiency of a set of decision-making units (DMUs). DEA forms an efficient combination of inputs and outputs to make an efficient frontier (Ayanso & Mokaya, 2013; Troutt et al., 2000). A DMU is efficient if it lies on the efficiency frontier; otherwise, it is inefficient. Charnes et al. (1978) (CCR) and Banker et al. (1984) (BCC) are two basic DEA models. Because of the advantages of DEA, it has been used in many areas over the last decades (Emrouznejad & Yang, 2018). However, there are some issues with standard DEA models. Firstly, there might be ratio data in performance evaluations. To deal with the ratio data, some approaches have been developed by scholars (e.g., Emrouznejad & Amin, 2009; Hatami-Marbini & Toloo, 2019; Henriques et al., 2020; Hollingsworth & Smith, 2003). Furthermore, the traditional DEA models assume that all the values are real numbers. Nevertheless, in many real-world applications, there might be integer inputs and outputs. To address this issue, Lozano and Villa (2006) were the first to propose integer-valued DEA. Matin and Kuosmanen (2009) improved the model proposed by Lozano and Villa (2006). Over the last few years, there has



been some research in the field of DEA and integer data (Azadi & Farzipoor Saen, 2014; Chen et al., 2012; Khoveyni et al., 2019; Kordrostami et al., 2019; Wu & Zhou, 2015). Moreover, the conventional DEA models assume that the inputs and outputs are positive, while there might be negative and zero data. Our literature survey shows that over the last few years, some scholars have endeavoured to tackle this issue (e.g., Allahyar & Rostamy-Malkhalifeh, 2015; Charnes et al., 1985; Chen & Liang, 2011; Cheng et al., 2013; Emrouznejad et al., 2010; Izadikhah & Farzipoor Saen, 2016; Khoveyni et al., 2017; Lee & Zhu, 2012; Lin & Chen, 2018; Portela et al., 2004; Tavana et al., 2018; Tavassoli et al., 2015). Indeed, a weakness of standard DEA models is their inability to address uncertainty in data. To deal with stochastic data, some research has been conducted by Land et al. (1993), Olesen and Petersen (1995), Azadi and Farzipoor Saen (2011), and Izadikhah et al. (2020).

On the other hand, traditional DEA models deal with black box DMUs and ignore the internal components of DMUs. It is argued that ignoring the internal structure of DMUs may lead to misleading results (Mirhedayatian et al., 2014). For the first time, Färe and Grosskopf (1996) developed the network DEA. Since then, network DEA has been used in many areas (e.g., Azadi et al., 2014; Izadikhah et al., 2019; Kao & Hwang, 2010; Lewis & Sexton, 2004; Matin et al., 2022; Samavati et al., 2020). Recently, network DEA has been applied successfully to measure sustainable, resilient SCs (see Izadikhah et al., 2019; Matin et al., 2022; Goodarzian et al., 2021).

2.4 Research gaps

Despite the importance of evaluating healthcare SCs, our literature review shows that little research has been done, particularly in the face of a pandemic outbreak. On the other hand, the current approaches do not take both the sustainability and resilience aspects into account in the efficiency assessment of healthcare SCs. This is while addressing sustainability and resilience aspects in performance evaluation of SCs in other areas has been a hot topic for scholars and managers. In addition, many current approaches are not suitable for uncertain situations such as epidemic outbreaks in which there are unexpected and extreme disruptions in SCs. It should be noted that uncertainty in SCs is a specific type of risk management. Moreover, none of the existing approaches can deal with different types of data, including ratio, integer, stochastic, negative, and zero in efficiency measurement of DMUs. To address these gaps in the literature we propose a new network DEA for evaluating the sustainability and resilience of healthcare SCs in response to the COVID-19 pandemic outbreak.

3 Proposed method

In this section, we develop our new model to evaluate the sustainability and resilience of healthcare SCs in response to the COVID-19 pandemic outbreak. Table 1 depicts the used notation.

Izadikhah and Farzipoor Saen (2016) developed a network RDM model in the presence of negative data. They dealt with negative data as absolute values. Tavana et al. (2018) proposed a dynamic network RDM model in the presence of desirable and undesirable carry-overs as well as negative data. In this paper, given the models proposed by Izadikhah and Farzipoor Saen (2016) and Tavana et al. (2018), a novel network RDM model based on the non-radial directional distance function is developed. Moreover, the novel model takes into account the non-radial changes by which all the inefficiencies in inputs, outputs, and intermediate



Table 1 The notations	
j	The jth DMU
i	the ith input
r	The rth output
f	The f th intermediate
F	Total number of intermediate products, $F = F_1 \cup F_2$
I	Total number of inputs, $I = I_1 \cup I_2 \cup I_3$
R	Total number of outputs, $R = R_1 \cup R_2 \cup R_3$
F_1	Subsets of intermediate products with integer values
F_2	Subsets of intermediate products with stochastic values
I_1	The inputs of stage 1 with real data
I_2	The inputs of stage 2 with real data
I_3	The inputs of stage 3 with integer data
R_1	The undesirable outputs of stage 2 with integer data
R_2	The outputs of stage 2 with integer data
R_3	The outputs of stage 3 with real data
P	Probability
α	The acceptable error of stochastic numbers
DMU_o	The DMU under evaluation
<i>x</i> _{<i>io</i>}	The <i>i</i> th input of DMU_0
У <i>го</i> г ¹	The <i>r</i> th output of DMU $_o$ The <i>i</i> th input of DMU $_i$ for stage 1
x_{ij}^1 x^2	The <i>i</i> th input of DMU _j for stage 2
x_{ij}^2 x_{io}^1 x_{io}^2 y_{rj}^2	The <i>i</i> th input of DMU ₀ for stage 1
x ²	The <i>i</i> th input of DMU $_0$ for stage 2
v^2 .	The rth output of DMU_j for stage 2
y_{ro}^2	The rth output of DMU $_0$ for stage 2
z_{fj}	The fth intermediate factor of DMU _j for $f \in F_1$ with integer values
\widetilde{z}_{fj}	The fth intermediate factor of DMU _j for $f \in F_2$ with stochastic values
z_{fo}	The fth intermediate factor of DMU _o for $f \in F_1$ with integer values
\tilde{z}_{fo}	The fth intermediate factor of DMU _o for $f \in F_2$ with stochastic values
\overline{z}_{fj}	The mean of \widetilde{z}_{fj} for $f \in F_2$
\overline{z}_{fo}	The mean of \tilde{z}_{fo} for $f \in F_2$
Q_{fo}^{1z}	The bound of intermediate measures $f \in F_1$ for stage 1
\widetilde{R}_{fo}^{1z}	The random variable of bounds for intermediate measures, $f \in F_2$ for stage 1
Q_{fo}^{2z}	The bound of intermediate measures, $f \in F_1$ for stage 2
Q_{fo}^{2z} \widetilde{R}_{fo}^{2z} \overline{R}_{fo}^{2z}	The random variable of bounds for intermediate measures, $f \in F_2$ for stage 2
\overline{R}_{fo}^{2z}	The bound average of random intermediate measures, $f \in F_2$ for stage 2
\overline{R}_{fo}^{1z}	The bound average of random intermediate measures, $f \in F_2$ for stage 1




Table 1 (continued)

λ_j^1	The <i>j</i> th intensity variable of stage 1
λ_j^2	The <i>j</i> th intensity variable of stage 2
λ_j^2 l_f^1 t_r^2 s_r^2	The integer output of stage 1 for $f \in F_1$
t_r^2	The integer output of stage 2 for $r \in R_1$
s_r^2	The integer output of stage 2 for $r \in R_2$
a_i^2	The integer input of stage 2 for $i \in I_3$
ρ	The objective function value
R_{io}^{1x}	The bound of the input for stage 1
R_{io}^{2x}	The bound of the external input of stage 2
R_{io}^{1x} R_{io}^{2x} R_{ro}^{2y}	The bound of the output of stage $2, r \in R_3 \cup R_2$
G_{ro}^{2y}	The bound of the output of stage $2, r \in R_1$
β_i^{1x}	The nonnegative variable for reducing the input of stage 1
β_i^{2x}	The nonnegative variable for reducing the external input of stage 2
$\dot{\tau}_f^{2z}$	The nonnegative slack for reducing the input of stage 2 (Intermediate measures) for $f \in \mathcal{F}_2$
τ_f^{2z}	The nonnegative slack for reducing the input of stage 2 (Intermediate measures) for $f \in \mathcal{F}_1$
$\dot{\gamma}_f^{1z}$	The nonnegative surplus for increasing the output of stage 1 (Intermediate measures) for $f \in F_2$
γ_f^{1z}	The nonnegative surplus for increasing the output of stage 1 (Intermediate measures) for $f \in F_1$
$\dot{\delta}_r^{2y}$	The nonnegative variable for decreasing the undesirable output of stage $2, r \in R_1$
δ_r^{2y}	The nonnegative variable for increasing integer and deterministic outputs of stage $2, r \in R_2 \cup R_3$
E	The expected random variable
Var	The variance of random variable
φ^{-1}	The inverse of cumulative distribution function
\widehat{x}_{io}^{1x}	The <i>i</i> th improved input of DMU_o for stage 1
\hat{x}_{io}^{2x}	The <i>i</i> th improved input of DMU_o for stage 2
$\widehat{\mathbf{y}}_{ro}^{2y}$	The r th improved output of DMU $_o$ for stage 2
\widehat{z}_{fo}^{1z}	The f th improved intermediate measure of DMU_{o} as output of stage 1
\widehat{z}_{fo}^{2z}	The f th improved intermediate measure of DMU_o as input of stage 2
S	A random variable



Fig. 1 A two-stage network



measures are considered. Furthermore, the intermediate measures as outputs of the first stage and inputs of the second stage are discussed from different aspects. More importantly, our proposed model can simultaneously deal with stochastic data, integer data, zero data, negative data, ratio data, and undesirable outputs.

Assume that the stochastic factors are normally distributed. In the classical DEA approaches, the ratio data are converted to the fractions, and the numerator is considered as output and the denominator is considered as input. Despite the classical DEA approaches, here, the ratio data are dealt with directly. For the ratio inputs, the reduced inputs should be less than or equal to 100%. However, since the inputs should be reduced, no need to add a constraint to ensure that the reduced inputs should be less than or equal to 100%.

To deal with the negative data, one of the very first models mathematically formulated in DEA is the RDM model developed by Portela et al. (2004). There exist other papers that extended the basic RDM model. Here, the models of Portela et al. (2004) and Tavana et al. (2018) are extended. To consider all the factors' inefficiencies in the stages, the non-radial changes of factors are taken into account. Note that the intermediate measures as inputs of stage 2 are considered less than or equal to the outputs of stage 1. Also, the ranges are determined for the undesirable outputs. Finally, the integer data and the stochastic data are dealt with. Figure 1 shows a network with two stages.

As is seen in Fig. 1, the intermediate measure z_f is the output of stage 1 and the input of stage 2. In the intermediate measures, there might be stochastic elements as denoted by $\tilde{z}_f, \forall f \in F_2$. The other intermediate measures are integer $z_f, \forall f \in F_1$. The $x_i^1, i \in I_1$ is a deterministic input of stage 1. The $x_i^2, i \in I_2$ is a deterministic input of stage 2. The $x_i^2, i \in I_3$ is an integer input of stage 2. Consider that $I_1 \cup I_2 \cup I_3 = I$. Also, some outputs of stage 2 might be undesirable $y_r^2, r \in R_1$ and some might be an integer $y_r^2, r \in R_2$. The rest can be deterministic and desirable outputs $y_r^2, r \in R_3$. Note that $R_1 \cup R_2 \cup R_3 = R$ and $F_1 \cup F_2 = F$.

Given Expression (1), in model (4), the ranges of inputs and outputs of stage 1 are incorporated. All the ranges are non-negative. The outputs of stage 1 ($f \in F_2$), the intermediate measures, are stochastic and have a normal distribution.

$$\begin{split} R_{io}^{1x} &= x_{io}^{1} - \min\{x_{ij}^{1} | \forall j\}, \quad \forall i \in I_{1}; \\ Q_{fo}^{1z} &= \max\{z_{fo} | \forall j\} - z_{fo}, \quad \forall f \in F_{1}; \quad \tilde{R}_{fo}^{1z} = \max\{\tilde{z}_{fo} | \forall j\} - \tilde{z}_{fo}, \quad \forall f \in F_{2}; \end{split} \tag{1}$$

Given Expression (2), in model (5), the ranges of inputs and outps of stage 2 are incorporated.



$$\begin{split} R_{io}^{2x} &= x_{io}^2 - \min\{x_{ij}^2 | \forall j\}, \quad \forall i \in I_2 \cup I_3; \quad Q_{fo}^{2z} = z_{fo} - \min\{z_{fj} | \forall j\}, \quad \forall f \in F_1 \\ \tilde{R}_{fo}^{2z} &= \tilde{z}_{fo} - \min\left\{\tilde{z}_{fj} | \forall j\right\}, \quad \forall f \in F_2; \quad R_{ro}^{2y} = \max\left\{y_{rj}^2 | \forall j\right\} - y_{ro}^2, \quad \forall r \in R_2 \cup R_3; \\ G_{ro}^{2y} &= y_{ro}^2 - \min\left\{y_{rj}^2 | \forall j\right\}, \quad \forall r \in R_1 \end{split}$$

Note that the range of *i*th input of DMU_o in Expressions (1) and (2) equals the deduction of the smallest *i*th input of all DMUs from the *i*th input of DMU_o. Since consuming less input is better, the smallest *i*th input is considered in Expressions (1) and (2). Also, the range of *r*th output of DMU_o in Expressions (1) and (2) equals the deduction of the biggest *r*th output of all DMUs from the *r*th output of DMU_o. Since more output is better, the biggest *r*th output is considered in Expressions (1) and (2). Thus, there is no improvement room for the inputs and outputs that their ranges are zero. Note that since y_r^2 , $r \in R_1$ is an undesirable output, its range is defined as input.

The intermediate measures can be outputs of stage 1 and inputs of stage 2. If the intermediate measures are inputs, then Expression (2) is used. If the intermediate measures are outputs, then Expression (1) is used.

Expression (3) is the modified objective function of the RDM model. Despite the classical RDM model, Expression (3) deals with the non-radial changes of inputs, outputs, and intermediate measures. Thus, it can incorporate all the factors' inefficiencies into the model.

$$Max \ \rho = \sum_{i \in I_1} \beta_i^{1x} + \sum_{f \in F_1} \gamma_f^{1z} + \sum_{f \in F_2} \dot{\gamma}_f^{1z} + \sum_{i \in I_2 \cup I_3} \beta_i^{2x}$$

$$+ \sum_{f \in F_2} \dot{\tau}_f^{2z} + \sum_{f \in F_1} \tau_f^{2z} + \sum_{r \in R_2 \cup R_3} \delta_r^{2y} + \sum_{r \in R_1} \dot{\delta}_r^{2y}$$
(3)

Model (4) is developed for stage 1. Constraint (b) corresponds with the non-radial reduction of ratio inputs. To deal with ratio inputs, we set the corresponding reductions in a way that its reduced input remains between 0 and 100%. Thus, $0 \le x_{io}^1 - \beta_i^{1x} R_{io}^{1x} \le 100$ should be added to the model. However, since the inputs are supposed to be decreased, the constraint is redundant and can be omitted. Constraints (c) are related to the integer outputs of stage 1. In constraints (c), the corresponding improved factor gets integer values. Thus, $l_f^1 = z_{fo} + \gamma_f^{1z} Q_{fo}^{1z}$ is considered in the model where $l_f^1 \in Z$. Constraint (d) is associated with the stochastic outputs of stage 1. Constraints (e) imply the variable returns to scale (VRS) assumption and the non-negativity of the variables. Note that the objective function of model (4) is similar to (3). The only difference is that the objective function of model (4) deals with stage 1.



(a)

$$\begin{aligned} & Max \ \rho = \sum_{i \in I_{1}} \beta_{i}^{1x} + \sum_{f \in F_{1}} \gamma_{f}^{1z} + \sum_{f \in F_{2}} \dot{\gamma}_{f}^{1z} \\ & s.t. \\ & \sum_{j=1}^{n} \lambda_{j}^{1} x_{ij}^{1} \leq x_{io}^{1} - \beta_{i}^{1x} R_{io}^{1x}, \\ & \sum_{j=1}^{n} \lambda_{j}^{1} z_{fj} \leq x_{io}^{1} - \beta_{i}^{1x} R_{io}^{1x}, \\ & \forall i \in I_{1} \quad (b) \\ & \sum_{j=1}^{n} \lambda_{j}^{1} z_{fj} \geq l_{f}^{1} \ l_{f}^{1} = z_{fo} + \gamma_{f}^{1z} Q_{fo}^{1z}, \\ & P\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} \geq \tilde{z}_{fo} + \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z}\right) \geq 1 - \alpha, \\ & P\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} \geq \tilde{z}_{fo} + \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z}\right) \geq 1 - \alpha, \\ & \nabla i \in F_{2} \quad (d) \\ & \sum_{j=1}^{n} \lambda_{j}^{1} = 1, \lambda_{j}^{1} \geq 0, \beta_{i}^{1x} \geq 0, \dot{\gamma}_{f}^{1z} \geq 0, l_{f}^{1} \in Z \ \forall j, \forall i, \forall f \ (e) \end{aligned}$$

Now, model (5) is developed for stage 2. The objective function of model (5) deals with stage 2. Constraint (f) is associated with the external inputs ($i \in I_2$) of stage 2, which are reduced non-radially. Constraints (g) are related to the integer external inputs ($i \in I_3$) of stage 2. In Constraints (g), the corresponding improved factor gets integer values. Thus, $a_i^2 = x_{io}^2 - \beta_i^{2x} R_{io}^{2x}$, where $a_i^2 \in Z$ is added to the model. Constraints (h) correspond to integer intermediate measures ($F \in F_1$). For this constraint, the corresponding improved factor gets integer values. Thus, $l_f^2 = z_{fo} - \dot{\tau}_f^{2z} Q_{fo}^{2z}$, where $l_f^2 \in Z$ is added to the model. Constraint (l) is associated with the stochastic intermediate measure. Constraints (p) are related to the integer and undesirable outputs of stage 2, which are considered inputs of stage 2. Note that according to the definition of ranges in (2), the range of undesirable outputs is similar to the range of inputs. Constraints (q) are associated with the integer outputs of stage 2. The corresponding improved factor gets integer values. Thus, $s_r^2 = y_{ro}^2 + \delta_r^{\hat{y}} R_{ro}^{\hat{y}} \in Z, r \in R_2$ is added to the model. Constraint (t) is related to the outputs of stage 2, which can be positive, zero, and negative. Constraints (u) and (w) imply the VRS and the non-negativity of the variables.

$$\begin{aligned} & \textit{Max } \rho = \sum_{i \in I_2 \cup I_3} \beta_i^{2x} + \sum_{f \in F_2} \dot{\tau}_f^{2z} + \sum_{f \in F_1} \tau_f^{2z} + \sum_{r \in R_2 \cup R_3} \delta_r^{2y} + \sum_{r \in R_1} \dot{\delta}_r^{2y} \\ & \textit{s.t.} \\ & \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq x_{ij}^2 - \beta_i^{2x} R_{io}^{2x}, \\ & \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq a_i^2, \ a_i^2 = x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, \\ & \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq a_i^2, \ a_i^2 = x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, \\ & \sum_{j=1}^n \lambda_j^2 z_{fj} \leq l_f^2, \ l_f^2 = z_{fo} - \dot{\tau}_f^{2z} Q_{fo}^{2z} \\ & \forall f \in F_2, \ (h) \\ & P\left(\sum_{j=1}^n \lambda_j^2 \tilde{z}_{fj} \leq \tilde{z}_{fo} - \tau_f^{2z} \tilde{R}_{fo}^{2z}\right) \geq 1 - \alpha, \\ & \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \leq t_r^2, \ t_r^2 = y_{ro}^2 - \dot{\delta}_r^y G_{ro}^y, \\ & \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq s_r^2, \ s_r^2 = y_{ro}^2 + \delta_r^y R_{ro}^y, \\ & \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq y_{ro}^2 + \delta_r^{2y} R_{ro}^{2y}, \\ & \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq y_{ro}^2 + \delta_r^{2y} R_{ro}^{2y}, \\ & \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq y_{ro}^2 + \delta_r^{2y} R_{ro}^{2y}, \\ & \sum_{j=1}^n \lambda_j^2 = \lambda_j^2 \geq 0, \ \beta_i^{2x} \geq 0, \ \delta_r^{2y} \geq 0, \ l_f^2, t_r^2, s_r^2, a_i^2 \in Z \\ & \forall j, i, r, \ (u) \\ & \tau_f^{2z} \geq 0, \ \dot{\tau}_f^{2z} \geq 0, \ \dot{\sigma}_f^{2y} \geq 0 \end{aligned}$$



If the range of inputs and outputs, for each stage, is zero, then there is no room for improvement as these already include the smallest and the largest outputs. Thus, it is clear that there is no room for reducing the inputs and increasing the outputs. Therefore, their associated variables β_i^{1x} , $\dot{\gamma}_f^{1z}$, γ_f^{1z} , β_i^{2x} , τ_f^{2z} , $\dot{\tau}_f^{2z}$, $\dot{\delta}_r^{2y}$, and δ_r^{2y} are zero. To deal with stochastic data, chance-constrained programming is one of the main methods in DEA (Cooper et al., 2002).

Lemma 1 Constraint (d) of model (4) is converted to the deterministic constraint as follows:

$$P\left(\sum_{j=1}^{n} \lambda_j^1 \tilde{z}_{fj} \ge \tilde{z}_{fo} + \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right) \ge 1 - \alpha, \quad \forall f \in F_2, \tag{6}$$

where α shows the risk level, which is between 0 and 1. The \tilde{z} and \tilde{R} random variables.

Constraint (d) can be written as follows:

$$P\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z} \ge 0\right) \ge 1 - \alpha, \quad \forall f \in F_{2}, \tag{7}$$

Assume that S is a random variable and d, a, e, and c are constants. If $P(S \ge d) = c$ and e > d, then the numbers like a < c can be found where $P(S \ge e) = a$ (Hosseinzadeh Lotfi et al., 2011). Thus, for each f, constraint (7) can be written as follows:

$$P\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z} \ge 0\right) = 1 - \alpha + \varepsilon_{f}, \quad \forall f \in F_{2}, \tag{8}$$

$$P\left(\sum_{j=1}^{n} \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z} \ge S_f\right) = 1 - \alpha, \quad \forall f \in F_2, \tag{9}$$

Assuming $\sum_{j=1}^{n} \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z} = h_f$, we have

$$P\left(\frac{h_f - E\left(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right)}{\sqrt{Var\left(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right)}} \le \frac{S_f - E\left(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right)}{\sqrt{Var\left(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right)}}\right)$$

$$= \alpha, \forall f \in F_2,$$

(10)

Assume that D_f is defined as follows:

$$D_{f} = \frac{h_{f} - E\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z}\right)}{\sqrt{Var\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z}\right)}}, \quad \forall f \in F_{2},$$

$$(11)$$

Expression (10) can be rewritten as follows:

$$P\left(D_f \le \frac{S_f - E\left(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right)}{\sqrt{Var\left(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\right)}}\right) = \alpha, \quad \forall f \in F_2, \tag{12}$$



The φ is the cumulative function of normal distribution and \overline{z} is the average of \tilde{z} . The σ is the standard deviation. As discussed by Cooper et al. (2002), Expression (12) can be written as follows:

$$\varphi\left(\frac{S_f - \sum_{j=1}^n \lambda_j^1 \overline{z}_{fj} + \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z}}{\sqrt{Var\left(\sum_{j=1}^n \lambda_j^1 \widetilde{z}_{fj} - \widetilde{z}_{fo} - \dot{\gamma}_f^{1z} \widetilde{R}_{fo}^{1z}\right)}}\right) = \alpha, \quad \forall f \in F_2,$$

$$(13)$$

Given α , the inverse of the cumulative distribution function (φ) is as follows:

$$\varphi^{-1}(\alpha) = \frac{S_f - \sum_{j=1}^n \lambda_j^1 \overline{z}_{fj} + \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z}}{\sqrt{Var\left(\sum_{j=1}^n \lambda_j^1 \widetilde{z}_{fj} - \widetilde{z}_{fo} - \dot{\gamma}_f^{1z} \widetilde{R}_{fo}^{1z}\right)}}$$

$$= \frac{S_f - \sum_{j=1}^n \lambda_j^1 \overline{z}_{fj} + \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z}}{\sigma_f\left(\lambda^1, \dot{\gamma}\right)}, \quad \forall f \in F_2,$$

$$(14)$$

where

$$\sqrt{Var\left(\sum_{j=1}^{n} \lambda_{j}^{1} \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_{f}^{1z} \tilde{R}_{fo}^{1z}\right)} = \sigma_{f}(\lambda^{1}, \dot{\gamma}), \quad \forall f \in F_{2},$$
(15)

Thus, we have

$$S_f + \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z} = \sum_{j=1}^n \lambda_j^1 \overline{z}_{fj} + \varphi^{-1}(\alpha) \sigma_f (\lambda^1, \dot{\gamma}), \quad \forall f \in F_2,$$
 (16)

Note that, in the optimisation models, the stochastic relations are replaced by Expression (16). Given the $\sigma_f(\lambda^1, \dot{\gamma})$, it is clear that Expression (16) is quadratic. Using the following expression, Expression (16) can be simplified as follows:

$$S_f + \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z} \ge 0, \quad S_f \ge 0, \quad \forall f \in F_2, \tag{17}$$

As a result, constraint (d) in model (4) can be written as follows:

$$\sum_{j=1}^{n} \lambda_{j}^{1} \overline{z}_{fj} + \varphi^{-1}(\alpha) \sigma_{f}(\lambda^{1}, \dot{\gamma}) \geq \overline{z}_{fo} + \dot{\gamma}_{f}^{1z} \overline{R}_{fo}^{1z}, \quad \forall f \in F_{2},$$

$$(18)$$

To calculate the variance of the outputs we have

$$\begin{split} \sigma_f^2\Big(\lambda^1,\dot{\gamma}\Big) &= Var\Bigg(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} - \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \, \tilde{R}_{fo}^{1z}\Bigg) = Var\Bigg(\sum_{j=1}^n \lambda_j^1 \tilde{z}_{fj} + (\lambda_o^1 - 1) \tilde{z}_{fo} - \dot{\gamma}_f^{1z} \tilde{R}_{fo}^{1z}\Bigg) \\ &\sum_{j=1}^n \left(\lambda_j^1\right)^2 Var\Big(\tilde{z}_{fj}\Big) + (\lambda_o^1 - 1)^2 Var\Big(\tilde{z}_{fo}\Big) + \Big(\dot{\gamma}_f^{1z}\Big)^2 Var\Big(\tilde{R}_{fo}^{1z}\Big) \\ &j=1 \\ &j\neq o \end{split}$$



$$+2COV\left(\sum_{j=1}^{n}\lambda_{j}^{1}\tilde{z}_{fj},(\lambda_{o}^{1}-1)\tilde{z}_{fo}\right)2COV\left(\sum_{j=1}^{n}\lambda_{j}^{1}\tilde{z}_{fj},\dot{\gamma}_{f}^{1z},\tilde{R}_{fo}^{1z}\right)\\ -2COV\left((\lambda_{o}^{1}-1)\tilde{z}_{fo},\dot{\gamma}_{f}^{1z},\tilde{R}_{fo}^{1z}\right),\ \ \forall f\in F_{2},$$

$$(19)$$

For simplicity, the covariance is assumed to be zero and the following expression is obtained:

$$\sigma_f^2(\lambda^1, \dot{\gamma}) = \sum_{j=1}^n (\lambda_j^1)^2 Var(\tilde{z}_{fj}) + (\lambda_o^1 - 1)^2 Var(\tilde{z}_{fo}) + (\dot{\gamma}_f^{1z})^2 Var(\tilde{R}_{fo}^{1z}), \quad \forall f \in F_2$$

$$j = 1$$

$$j \neq o$$
(20)

For the other stochastic constraints of stage 2, the final variance is as follows:

$$\sigma_f^2(\lambda^2, \tau) = \sum_{\substack{j=1\\j\neq o}}^n (\lambda_j^2)^2 Var(\tilde{z}_{fj}) + (\lambda_o^2 - 1)^2 Var(\tilde{z}_{fo}) + (\tau_f^{2z})^2 Var(\tilde{R}_{fo}^{2z}), \quad \forall f \in F_2$$
(21)

Using the chance-constrained programming approach, constraint (d) in model (4) and constraints (l) and (h) in model (5) can be written as follows:

$$\sum_{j=1}^{n} \lambda_{j}^{1} \overline{z}_{fj} + \varphi^{-1}(\alpha) \ \sigma_{f}(\lambda^{1}, \dot{\gamma}) \geq \overline{z}_{fo} + \dot{\gamma}_{f}^{1z} \ \overline{R}_{fo}^{1z}, \quad \forall f \in F_{2}$$

$$\sum_{j=1}^{n} \lambda_{j}^{2} \overline{z}_{fj} - \varphi^{-1}(\alpha) \ \sigma_{f}(\lambda^{2}, \tau) \leq \overline{z}_{fo} - \tau_{f}^{2z} \ \overline{R}_{fo}^{2z}, \quad \forall f \in F_{2}$$

$$(22)$$

Models (4) and (5) are quadratic programming problems, and their deterministic versions are presented in models (23) and (24).

$$\begin{aligned} & Max \ \rho = \sum_{i \in I_{1}} \beta_{i}^{1x} + \sum_{f \in F_{1}} \gamma_{f}^{1z} + \sum_{f \in F_{2}} \dot{\gamma}_{f}^{1z} \\ & s.t. \\ & \sum_{j=1}^{n} \lambda_{j}^{1} x_{ij}^{1} \leq x_{io}^{1} - \beta_{i}^{1x} R_{io}^{1x}, & \forall i \in I_{1}, \ (b) \\ & \sum_{j=1}^{n} \lambda_{j}^{1} z_{fj} \geq l_{f}^{1}, \quad l_{f}^{1} = z_{fo} + \gamma_{f}^{1z} Q_{fo}^{1z}, & \forall f \in F_{1}, \ (c) \\ & \sum_{j=1}^{n} \lambda_{j}^{1} \overline{z}_{fj} + \varphi^{-1}(\alpha) \sigma_{f}(\lambda^{1}, \dot{\gamma}) \geq \overline{z}_{fo} + \dot{\gamma}_{f}^{1z} \overline{R}_{fo}^{1z}, & \forall f \in F_{2}, \ (d) \\ & \sum_{j=1}^{n} \lambda_{j}^{1} = 1, \ \lambda_{j}^{1} \geq 0, \beta_{i}^{1x} \geq 0, \dot{\gamma}_{f}^{1z} \geq 0, \gamma_{f}^{1z} \geq 0, l_{f}^{1} \in Z \ \forall j, i, f, \ (e) \end{aligned}$$

Consider model (24) as follows:



$$\begin{aligned} &Max \; \rho = \sum_{i \in I_2 \cup I_3} \beta_i^{2x} + \sum_{f \in F_1} \dot{\tau}_f^{2z} + \sum_{f \in F_2} \tau_f^{2z} + \sum_{r \in R_2 \cup R_3} \delta_r^{2y} + \sum_{r \in R_1} \dot{\delta}_r^{2y} \\ &s.t. \\ &\sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, & \forall i \in I_2 \quad (f) \\ &\sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq a_i^2, \quad a_i^2 = x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, & \forall i \in I_3, \quad (g) \\ &\sum_{j=1}^n \lambda_j^2 z_{fj} \leq l_f^2, \; l_f^2 = z_{fo} - \dot{\tau}_f^{2z} \; Q_{fo}^{2z}, & \forall f \in F_1, \quad (h) \\ &\sum_{j=1}^n \lambda_j^2 \overline{z}_{fj} - \varphi^{-1}(\alpha) \sigma_f(\lambda^2, \tau) \leq \overline{z}_{fo} - \tau_f^{2z} \overline{R}_{fo}^{2z}, & \forall f \in F_2, \quad (l) \\ &\sum_{j=1}^n \lambda_j^2 y_{rj}^2 \leq t_r^2, \quad t_r^2 = y_{ro}^2 - \dot{\delta}_r^{2y} G_{ro}^{2y}, & \forall r \in R_1, \quad (p) \\ &\sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq s_r^2, \quad s_r^2 = y_{ro}^2 + \delta_r^{2y} \; R_{ro}^{2y}, & \forall r \in R_2, \quad (q) \\ &\sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq y_{ro}^2 + \delta_r^{2y} R_{ro}^{2y} & \forall r \in R_3, \quad (t) \\ &\sum_{j=1}^n \lambda_j^2 = 1, \lambda_j^2 \geq 0, \, \beta_i^{2x} \geq 0, \, \tau_f^{2z} \geq 0, \, \dot{\tau}_f^{2z} \geq 0, \, \dot{t}_f^2, \, a_i^2, \, t_r^2, \, s_r^2 \in Z \quad \forall j, i, f, \quad (u) \\ &\delta_r^{2y} \geq 0, \, \dot{\delta}_r^{2y} \geq 0, & \forall r, \quad (w) \end{aligned}$$

Model (25) assesses the overall efficiency of supply chains.

$$\begin{aligned} & \text{Max } \rho = \sum_{i \in I_1} \beta_i^{1x} + \sum_{f \in F_1} \gamma_f^{1z} + \sum_{f \in F_2} \dot{\gamma}_f^{1z} \\ & + \sum_{i \in I_2 \cup I_3} \beta_i^{2x} + \sum_{f \in F_1} \dot{\tau}_f^{2z} + \sum_{f \in F_2} \tau_f^{2z} + \sum_{r \in R_2 \cup R_3} \delta_r^{2y} + \sum_{r \in R_1} \dot{\delta}_r^{2y} \\ & \text{s.t.} \end{aligned}$$

$$& \text{s.t.}$$

$$& \sum_{j=1}^n \lambda_j^1 x_{ij}^1 \leq x_{io}^1 - \beta_i^{1x} R_{io}^{1x}, \qquad \forall i \in I_1, \quad (a)$$

$$& \sum_{j=1}^n \lambda_j^1 z_{fj} \geq l_f^1, \quad l_f^1 = z_{fo} + \gamma_f^{1z} Q_{fo}^{1z}, \qquad \forall f \in F_1, \quad (b)$$

$$& \sum_{j=1}^n \lambda_j^1 \overline{z}_{fj} + \varphi^{-1}(\alpha) \sigma_f(\lambda^1, \dot{\gamma}) \geq \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z}, \qquad \forall f \in F_2, \quad (c)$$

$$& \sum_{j=1}^n \lambda_j^1 \overline{z}_{fj} + \varphi^{-1}(\alpha) \sigma_f(\lambda^1, \dot{\gamma}) \geq \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z}, \qquad \forall f \in F_2, \quad (c)$$

$$& \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, \qquad \forall i \in I_2, \quad (e)$$

$$& \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq a_i^2, \quad a_i^2 = x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, \qquad \forall i \in I_3, \quad (f)$$

$$& \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq a_i^2, \quad a_i^2 = x_{io}^2 - \beta_i^{2x} R_{io}^{2x}, \qquad \forall f \in F_1, \quad (g)$$

$$& \sum_{j=1}^n \lambda_j^2 x_{ij}^2 \leq l_f^2, \quad l_f^2 = z_{fo} - \dot{\tau}_f^{2z} Q_{fo}^{2z}, \qquad \forall f \in F_2, \quad (h)$$

$$& \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \leq l_r^2, \quad t_r^2 = y_{ro}^2 - \dot{\delta}_r^{2y} G_{ro}^{2y}, \qquad \forall r \in R_1, \quad (p)$$

$$& \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq s_r^2, \quad s_r^2 = y_{ro}^2 + \delta_r^{2y} R_{ro}^{2y}, \qquad \forall r \in R_3, \quad (t)$$

$$& \sum_{j=1}^n \lambda_j^2 y_{rj}^2 \geq y_{ro}^2 + \delta_r^{2y} R_{ro}^{y}, \qquad \forall r \in R_3, \quad (t)$$

$$& \sum_{j=1}^n \lambda_j^2 = 1, \lambda_j^2 \geq 0, \beta_i^{2x} \geq 0, \tau_f^{2z} \geq 0, \dot{\tau}_f^{2z} \geq 0, l_f^2, a_i^2, l_r^2, s_r^2 \in Z \quad \forall j, i, f, \quad (u)$$

$$& \delta_r^{2y} \geq 0, \delta_r^{2y} \geq 0, 0, \qquad \forall r$$



Theorem 1 Models (23), (24), and (25) are always feasible and bounded.

Proof Without loss of generality, assume that, except for o, for each j we have $\lambda_j^1 = 0$ and $\lambda_j^2 = 0$. If $\lambda_o^1 = 1$, $\lambda_o^2 = 1$, and the rest of the variables are zero, a feasible solution is obtained for every level of α .

$$\sum_{j=1}^{n} \lambda_{j}^{1} \overline{z}_{fj} + \varphi^{-1}(\alpha) \sigma_{f}(\lambda^{1}, \gamma) \geq \sum_{j=1}^{n} \lambda_{j}^{1} \overline{z}_{fj} \geq \overline{z}_{fo} + \dot{\gamma}_{f}^{1z} \overline{R}_{fo}^{1z},$$

$$\dot{\gamma}_{f}^{1z} \leq \frac{\sum_{j=1}^{n} \lambda_{j}^{1} \overline{z}_{fj} - \overline{z}_{fo}}{\overline{R}_{fo}^{1z}}, \quad \forall f \in F_{2}$$
(26)

Similarly, the same approach applies to other inequalities. As a result, the solution is bounded. Note that if $\alpha = 0.5$, then $\varphi^{-1}(\alpha) = 0$, and the deterministic equivalent is obtained. Note that the data are assumed to have positive values with normal distribution.

Theorem 2 In the optimal solution of models (23), (24), and (25), all the constraints are binding.

Proof Assume that at least one constraint is strictly unequal (not binding). Thus, to change the inequality to equality, there exist fewer inputs for the input constraints and more outputs for the output constraints. As a result, the better solution violates the optimality, the assumption is invalidated, and the theorem is proven.

We will now discuss the changes in each factor. Without loss of generality, one of the input's constraints is as follows:

$$\sum_{j=1}^{n} \lambda_{j}^{1} x_{ij}^{1} \le x_{io}^{1} - \beta_{i}^{1x} R_{io}^{1x}, \ \forall i \to \beta_{i}^{1x} \le \frac{x_{io}^{1} - \sum_{j=1}^{n} \lambda_{j}^{1} x_{ij}^{1}}{R_{io}^{1x}}$$
 (27)

Since in the optimality, every constraint has an equal sign, we have

$$\beta_i^{*1x} = \frac{x_{io}^1 - \sum_{j=1}^n \lambda_j^{1*} x_{ij}^1}{R_{io}^{1x}}, \quad \forall i \in I_1$$
 (28)

Note that there is slack in the numerator as it is the difference between the input of the DMU_o and the efficiency frontier. Also, the denominator shows the range. The same discussion applies to the rest of the inputs.

Since in the optimality the associated constraint has an equal sign, Expression (29) exists for the first constraint. Note that the numerator of Expression (29) plays the role of slack as it is the difference between the average output of DMU_o and the stochastic efficiency frontier. Also, the denominator shows the range. As demonstrated, the numerator is less than the denominator. In Expression (29), for each r, the γ_r^{*1y} indicates the associated inefficiency of the factors.

$$\dot{\gamma}_{f}^{*1z} = \frac{\sum_{j=1}^{n} \lambda_{j}^{*1} \overline{z}_{fj} + \varphi^{-1}(\alpha) \ \sigma_{f}(\lambda^{1}, \dot{\gamma}) - \overline{z}_{fo}}{\overline{R}_{fo}^{1z}}$$

$$= \frac{\sum_{j=1}^{n} \lambda_{j}^{*1} \overline{z}_{fj} + \varphi^{-1}(\alpha) \ \sigma_{f}(\lambda^{1}, \dot{\gamma}) - \overline{z}_{fo}}{\max\{z_{fj} | \forall j\} - z_{fo}}, \quad \forall f \in F_{2}$$
(29)



Definition 1 Without loss of generality, consider the input constraint of Model (23). The efficiency of the input is defined as follows:

$$E_i^1 = 1 - \beta_i^{*1x}, \ \forall i \tag{30}$$

where

$$\beta_i^{*x} = \frac{x_{io}^1 - \sum_{j=1}^n \lambda_j^{1*} x_{ij}^1}{R_{io}^{1x}}$$
(31)

$$1 - \beta_{i}^{*x} = 1 - \frac{x_{io}^{1} - \sum_{j=1}^{n} \lambda_{j}^{1*} x_{ij}^{1}}{R_{io}^{1x}} = 1 - \frac{x_{io}^{1} - \sum_{j=1}^{n} \lambda_{j}^{1*} x_{ij}^{1}}{x_{io}^{1} - \min\{x_{ij}^{1} | \forall j\}}$$

$$= \frac{x_{io}^{1} - \min\{x_{ij}^{1} | \forall j\} - x_{io}^{1} + \sum_{j=1}^{n} \lambda_{j}^{1*} x_{ij}^{1}}{x_{io}^{1} - \min\{x_{ij}^{1} | \forall j\}}, \ \forall i$$
(32)

Thus, we can write

$$1 - \beta_i^{*x} = \frac{\sum_{j=1}^n \lambda_j^{1*} x_{ij}^1 - \min\{x_{ij}^1 | \forall j\}}{x_{io}^1 - \min\{x_{ij}^1 | \forall j\}}, \quad \forall i$$
 (33)

Since $\sum_{j=1}^{n} \lambda_{j}^{1*} x_{ij}^{1}$ is always less than or equal to x_{io}^{1} , then

$$1 - \beta_i^{*x} \le 1, \quad \forall i \in I_1 \tag{34}$$

Consider the output of stage 1. Since $0 \le \gamma_f^{*1z} \le 1$, the output efficiency is defined as follows:

$$1 + \gamma_f^{*1z} \ge 1, \quad \forall f \in F_1 \tag{35}$$

The same holds for the decision variables of inputs and outputs of stages 1 and 2.

Lemma 2 If the range of inputs, outputs, and intermediate measures of DMU_o is zero, there is no room for their improvements.

Proof The zero range implies that the associated factors have the smallest input and the biggest output. In this case, the associated constraint is considered with an equal sign. For instance, consider the input constraint with zero range.

$$\sum_{i=1}^{n} \lambda_{j}^{1} x_{ij}^{1} = x_{io}^{1} - \beta_{i}^{*1x} x_{io}^{1} = \left(1 - \beta_{i}^{*1x}\right) x_{io}^{1} \to \beta_{i}^{*1x} = 0 \quad \forall i \in I_{1}$$
 (36)

The same reasoning applies to other constraints.

Using the objective function of model (25), the total efficiency (TE) is calculated as follows:

follows:
$$TE = \frac{1}{1+\rho}$$

$$= \frac{1}{1 + \sum_{i \in I_1} \beta_i^{*1x} + \sum_{f \in F_1} \gamma_f^{*1z} + \sum_{f \in F_2} \dot{\gamma}_f^{*1z} + \sum_{i \in I_2 \cup I_3} \beta_i^{*2x} + \sum_{f \in F_1} \dot{\tau}_f^{*2z} + \sum_{f \in F_2} \tau_f^{*2z} + \sum_{r \in R_2 \cup R_3} \delta_r^{*2y} + \sum_{r \in R_1} \dot{\delta}_r^{*2y}}$$
(37)



Using the objective function of model (23), the efficiency of stage 1 (ES_1) is as follows:

$$ES_1 = \frac{1}{1 + \sum_{i \in I_1} \beta_i^{*1x} + \sum_{f \in F_1} \gamma_f^{*1z} + \sum_{f \in F_2} \dot{\gamma}_f^{*1z}}$$
(38)

Using the objective function of model (24), the efficiency of stage 2 (ES_2) is as follows:

$$ES_{2} = \frac{1}{1 + \sum_{i \in I_{2} \cup I_{3}} \beta_{i}^{*2x} + \sum_{f \in F_{2}} \dot{\tau}_{f}^{*2z} + \sum_{f \in F_{1}} \tau_{f}^{*2z} + \sum_{r \in R_{2} \cup R_{3}} \delta_{r}^{*2y} + \sum_{r \in R_{1}} \dot{\delta}_{r}^{*2y}}$$
(39)

Theorem 3 The efficiency scores obtained from Expressions (37), (38), and (39) are as follows:

$$TE < 1, ES_1 < 1, ES_2 < 1$$
 (40)

Proof Since the associated variables of inputs and outputs are non-negative, in optimality we have

$$\beta_i^{*1x} \geq 0, \dot{\gamma}_f^{*1z} \geq 0, \gamma_f^{*1z} \geq 0, \beta_i^{*2x} \geq 0, \tau_f^{*2z} \geq 0, \dot{\tau}_f^{2z} \geq 0, \delta_r^{*2y} \geq 0, \dot{\delta}_r^{*2y} \geq 0 \quad (41)$$

Therefore, given Expressions (37), (38), (39), and (41), the efficiency scores are always less than or equal to one. \Box

Theorem 4 In models (23), (24), and (25), given the VRS technology, the DMUs with the smallest input and biggest output are efficient, and there is no room for improvement in the factors.

Proof Given Expressions (1) and (2), if the DMU_o has the smallest input and the biggest output, then its associated variable in models (23), (24), and (25) is considered zero, and there is no room for improvement. Otherwise, if the range is non-zero, then the DMU_o can improve its performance.

$$\min\{x_{ij}^1 | \forall j\} = x_{io}^1 \to R_{io}^{1x} = x_{io}^1 - \min\{x_{ij}^1 | \forall j\} = x_{io}^1 - x_{io}^1 = 0, \quad \forall i$$
 (42)

The same holds for other ranges as defined in (1) and (2). If the DMU_o has positive changes for inputs and outputs, then it is inefficient. The more changes, the less efficiency of DMU_o. \Box

The improved factors of the first stage are determined as follows:

$$\hat{z}_{fo}^{1z} = z_{fo} + \gamma_f^{1z} R_{fo}^{1z}, \quad \forall f \in F_1
\hat{z}_{fo}^{1z} = \overline{z}_{fo} + \dot{\gamma}_f^{1z} \overline{R}_{fo}^{1z}, \quad \forall f \in F_2
\hat{x}_{io}^{1x} = x_{io}^1 - \beta_i^{1x} R_{io}^{1x}, \quad \forall i \in I_1$$
(43)

The improved factors of the second stage are determined as follows:

$$\hat{x}_{io}^{2x} = x_{io}^{2} - \beta_{i}^{2x} R_{io}^{2x}, \quad \forall i \in I_{1} \cup I_{2}
\hat{z}_{fo}^{2z} = z_{fo} - \dot{\tau}_{f}^{2z} R_{fo}^{2z}, \quad \forall f \in F_{2}; \quad \hat{z}_{fo}^{2z} = \overline{z}_{fo} - \tau_{f}^{2z} \overline{R}_{fo}^{2z}, \quad \forall f \in F_{1}
\hat{y}_{ro}^{2y} = y_{ro}^{2} - \dot{\delta}_{r}^{2y} G_{ro}^{2y}, \quad \forall r \in R_{1}; \quad \hat{y}_{ro}^{2y} = y_{ro}^{2} + \delta_{r}^{2y} R_{ro}^{2y}, \quad \forall r \in R_{2} \cup R_{3}$$
(44)

Theorem 5 The obtained improved factors in (43) and (44) are Pareto efficient.



Proof Assume that an improved factor does not lie on the Pareto efficiency frontier. Thus, the improved factor is dominated by the other dominant point. The dominant point has a better solution in the objective function. This violates the Pareto optimality and the theorem is proved.

Theorem 6 The objective functions of models (23), (24), and (25) are not greater than the DDF model.

Proof Without loss of generality, consider the input constraints in stage 1. The β_i^{1x} is the non-negative variable that changes the *i*th input. The R_{io}^{1x} is the range of the *i*th input of DMU_o. Given Expression (1), the range of input is as follows:

$$R_{io}^{1x} = x_{io}^{1} - \min\{x_{ij}^{1} | \forall j\}, \quad \forall i \in I_{1}$$
(45)

The improved inputs in the DDF model are as follows:

$$\hat{x}_{io}^{1x} = x_{io}^1 - \beta_i^{1x} x_{io}^1, \quad \forall i \in I_1$$
 (46)

To compare Expressions (45) and (46), we have

$$x_{io}^{1} - \beta_{i}^{1x} R_{io}^{1x} \ge x_{io}^{1} - \beta_{i}^{1x} x_{io}^{1}, \quad \forall i \in I_{1}$$

$$(47)$$

Given Expression (45), it is clear that $R_{io}^{1x} \le x_{io}^1$. Thus, the efficiency score of Expression (37) is less than or equal to the DDF model.

Theorem 7 Constraints of models (23), (24), and (25) are unit invariant and translation invariant.

Proof Without loss of generality, assume that $h_r \ \forall r \in R_1$ is added to the output of stage 2. Thus, we have

$$\sum_{i=1}^{n} \lambda_{j}^{2} \left(y_{rj}^{2} + h_{r} \right) \ge \left(y_{ro}^{2} + h_{r} \right) + \dot{\gamma}_{r}^{2y} R_{ro}^{2y}, \quad \forall r \in R_{3}$$
 (48)

Since $\sum_{j=1}^{n} \lambda_j^2 = 1$, we have

$$\sum_{j=1}^{n} \lambda_{j}^{2} y_{rj}^{2} + \sum_{j=1}^{n} \lambda_{j}^{2} h_{r} = \sum_{j=1}^{n} \lambda_{j}^{2} y_{rj}^{2} + (h_{r}) \sum_{j=1}^{n} \lambda_{j}^{2} = \sum_{j=1}^{n} \lambda_{j}^{2} y_{rj}^{2} + (h_{r})$$

$$\geq (y_{ro}^{2} + h_{r}) + \dot{\gamma}_{r}^{2y} R_{ro}^{2y}, \ \forall r \in R_{3}$$

$$(49)$$

Given Expression (2), by adding h_r , the ranges do not change. As a result,

$$\sum_{i=1}^{n} \lambda_{j}^{2} y_{rj}^{2} \ge y_{ro}^{2} + \dot{\gamma}_{r}^{2y} R_{ro}^{2y}, \quad \forall r \in R_{3}$$
 (50)

This proves that the model is a translation invariant. Now, assume that h_r is multiplied by the output. Thus, it is multiplied by the ranges. Therefore, we have

$$\sum_{i=1}^{n} \lambda_{j}^{2} \left(y_{rj}^{2} \times h_{r} \right) \ge \left(y_{ro}^{2} \times h_{r} \right) + \dot{\gamma}_{r}^{2y} \left(R_{ro}^{2y} \times h_{r} \right) \quad \forall r \in R_{3}$$
 (51)



Expression (51) can be written as follows:

$$\sum_{i=1}^{n} \lambda_{j}^{2} y_{rj}^{2} \ge y_{ro}^{2} + \dot{\gamma}_{r}^{2y} R_{ro}^{2y} \quad \forall r \in R_{3}$$
 (52)

Thus, constraint (t) of model (52) is unit invariant. This procedure can be performed for other constraints of inputs and outputs of stages 1 and 2.

Figure 2 represents two stages of the network. Note that both outputs of stage 1 are positive and an output of stage 2 is negative. Figure 2 shows the non-radial changes in the negative output.

The red line in stage 1 shows the direction of improvement for DMU K. Given Expression (1), the outputs' range of DMU K is (2, 4). Using model (23), DMU K is projected on K''', which lies on the efficiency frontier. For the second stage, the first output of DMU H is negative. If DMU H is assessed by the classical directional distance function model, it should be projected on the efficiency frontier given the vector \overrightarrow{OH} , marked by the blue colour. In




Fig. 2 The efficiency frontiers of stages 1 and 2



this case, the first output becomes more negative, which is worse. However, using Expression (2), it is projected on the efficiency frontier (point \acute{B}) by $\overrightarrow{HI_H}$, marked in red colour. Using Expression (2), it is clear that $I_H = (4.5, 4.5)$. Using the classic RDM model for stage 2, we have

$$\lambda_B^* = 0.67, \ \lambda_C^* = 0.33 \tag{53}$$

Consider β as radial alterations. As a result, its radial change is $\beta^* = 0.52$. Using model (24) the results are as follows:

$$\lambda_B^* = 1, \ \beta_1^{*y_1} = 0.67, \ \beta_2^{*y_2} = 0.44$$
 (54)

The average non-radial changes of outputs are $\rho^* = 0.55$. As is seen in Fig. 2 of stage 2, the radial projected point \hat{B} has a small difference with DMU B. However, due to the inclusion of all inefficiencies of outputs, the non-radial efficiency score is less than the radial efficiency score. By the non-radial change, DMU H is projected on DMU B, which is shown by the green vector. The point \hat{B} is obtained as follows.

$$y_1 = -0.5 + 0.52 \times 4.5 = 1.8 y_2 = 1.0 + 0.52 \times 4.5 = 3.3$$
 $\rightarrow \acute{B} = \begin{pmatrix} 1.8 \\ 3.3 \end{pmatrix}$ (55)

By equal radial change, both outputs are changed with coefficient 4.5 and point \hat{B} is obtained. Now, consider the triangle $H\hat{B}I_H$, which is marked in the red line. The non-radial changes of outputs are done separately, and the outputs of DMU H are increased. The $HP\hat{B}$ in Fig. 2 shows the increase. Given Fig. 2 of stage 2, it is clear that HP and $P\hat{B}$ have equal edges in the triangle. The non-radial changes in the outputs are as follows:

$$y_1 = -0.5 + 0.67 \times 4.5 = 2.5 y_2 = 1 + 0.44 \times 4.5 = 3$$
 $\rightarrow B = \begin{pmatrix} 2.5 \\ 3 \end{pmatrix}$ (56)

As is seen in Fig. 2 of stage 2, by $\beta_1^{*y_1} = 0.67$ and $\beta_2^{*y_2} = 0.44$, DMU H is projected on DMU B. Given Thales's theorem (Heilberg and Fitzpatrick, 2007) and the triangles $H B I_H$ and H P B, we get $\frac{HP}{HP} = \frac{BP}{I_HP}$. The interpretation of Fig. 2 for stage 1 is straightforward.

4 Case study

Iran is one of the most affected countries by COVID-19 disease, with over 726,000 total cases and 40,000 deaths by November 2020. At the moment of writing this paper, the country was experiencing a considerable increase in the number of COVID-19 infections and deaths. The sustainability and resilience of the healthcare SCs have received much attention during the course of this unprecedented pandemic. However, the efficiency of healthcare SCs in disaster situations such as pandemics can be largely affected due to the uncertainties of some key indicators such as increased demand, numerous SC disruptions, and shortages of vital medical equipment (Dolinskaya et al., 2018).

In this case study, we evaluate the sustainability and resilience of the healthcare SCs in Iran. In this study, healthcare SCs consist of suppliers (stage 1) and hospitals (stage 2). The suppliers manufacture COVID-19 testing kits. The kits detect new Coronavirus cases and are one of the most important medical devices. The inputs of stage 1 are raw material costs (x_1^1) , the rate of inferior raw material (x_2^1) , environmental costs (x_3^1) , and personnel costs (x_4^1) . The number of produced COVID-19 testing kits and the average inventory are intermediate






Fig. 3 The two-stage supply chain

measures, which exit from stage 1 and enter stage 2. The external inputs of stage 2 include employees' health and safety costs (x_1^2) , the number of personnel (x_2^2) , personnel costs (x_3^2) , the number of patients (x_4^2) , and the number of beds (x_5^2) . The outputs of stage 2 are the number of errors in diagnosing COVID-19 disease (y_1^2) , the number of discharged patients (y_2^2) , and profit (y_3^2) . Figure 3 shows the structure of healthcare SC.

Table (9 see Appendix) summarises the indicators. In this study, several meetings were held with managers and experts of suppliers and hospitals to identify the most important indicators for measuring the sustainability and resilience of healthcare SCs in response to the COVID-19 pandemic outbreak. Table (10 see Appendix) presents the dataset of 28 healthcare SCs. The dataset is related to March to June 2020, which is extracted by observing documents of suppliers and hospitals of healthcare SCs. ¹

4.1 Results and discussions

Given different α values, Table 2 reports the suppliers' efficiencies obtained from Expression (38). Considering Expression (38), the aim is to evaluate efficiency of the first stage of the network. As is seen, the higher α , the higher efficiency of DMUs. As an example, consider DMU 1. This DMU has an efficiency value of 0.627759 for $\alpha = 0.02$. As the value of error α increases, specifically considering $\alpha = 0.04$, the efficiency value of this unit is increased and becomes 0.628231. This upward trend continued for unit number 1 until at $\alpha = 0.1$ its efficiency value becomes 0.628949. DMUs 2, 5, 8, 9, 10, 15, 16, 20, 23, 25, and 26 have the same behavior as DMU 1, and their efficiencies are increased by increasing α . This means that by considering the variance of random data, different values of efficiency are obtained for each error level. This shows the effectiveness of the random nature of the data in this practical example. Now, consider DMU 3. This DMU has an efficiency value of 1 with all values of $\alpha = 0.02$, $\alpha = 0.04$, $\alpha = 0.06$, $\alpha = 0.08$, and $\alpha = 0.1$. For DMUs 3, 4, 6, 7, 11, 12, 13, 14, 17, 18, 19, 21, 22, 23, 24, 27, and 28, the efficiency stability is clearly shown by the constant efficiency value of 1 due to the increase of the error level value. This means that by increasing the error level, these DMUs maintain their unity efficiency. Also, changes of random data and their variance have no effect on the efficiency value.



¹ Note that we are not allowed to disclose the names of suppliers and hospitals.

Table 2 The stochastic efficiency of suppliers given different $\boldsymbol{\alpha}$ values

DMUs	The stochastic effi	ciencies given diffe	rent α values		
	$\alpha = 0.02$	$\alpha = 0.04$	$\alpha = 0.06$	$\alpha = 0.08$	$\alpha = 0.1$
DMU1	0.627759	0.628231	0.628532	0.628764	0.628949
DMU2	0.589897	0.590586	0.590782	0.591365	0.591636
DMU3	1	1	1	1	1
DMU4	1	1	1	1	1
DMU5	0.37022	0.370269	0.370298	0.370325	0.370344
DMU6	1	1	1	1	1
DMU7	1	1	1	1	1
DMU8	0.587171	0.587299	0.587342	0.587443	0.587493
DMU9	0.337343	0.337371	0.337401	0.337403	0.337414
DMU10	0.59735	0.597476	0.597568	0.597619	0.597669
DMU11	1	1	1	1	1
DMU12	1	1	1	1	1
DMU13	1	1	1	1	1
DMU14	1	1	1	1	1
DMU15	0.364907	0.365042	0.365098	0.365195	0.365249
DMU16	0.494152	0.494405	0.494564	0.49469	0.49479
DMU17	1	1	1	1	1
DMU18	1	1	1	1	1
DMU19	1	1	1	1	1
DMU20	0.465058	0.465124	0.465156	0.4652	0.465226

Table 2 (continued)

DMUs	The stochastic	efficiencies given d	lifferent α values		
	$\alpha = 0.02$	$\alpha = 0.04$	$\alpha = 0.06$	$\alpha = 0.08$	$\alpha = 0.1$
DMU21	1	1	1	1	1
DMU22	1	1	1	1	1
DMU23	0.373162	0.373285	0.373388	0.373424	0.373473
DMU24	1	1	1	1	1
DMU25	0.403753	0.403845	0.403879	0.40395	0.403986
DMU26	0.488223	0.488442	0.488513	0.488691	0.488777
DMU27	1	1	1	1	1
DMU28	1	1	1	1	1






Fig. 4 Summary of the results

Figure 4 summarises the results shown in Table 2.

Given different α values, Table 3 depicts the hospitals' efficiencies using Expression (39). Taking into consideration Expression (39), the efficiency of the second stage is investigated. As is seen, the higher α , the higher the efficiency of DMUs. According to Table 3, the efficiency of DMUs are calculated considering different levels of α . As is shown in Table 3, DMUs 1, 3, 11, 13, 15, 16, 17, 18, 19, 21, 22, 23, 24, 26, and 27, in all error levels, are inefficient. The efficiency of these DMUs is increased by increase in the error level. Note that DMUs 8 and 28 are inefficient in $\alpha = 0.02$ and $\alpha = 0.04$. By increasing the error level to $\alpha = 0.06$, $\alpha = 0.08$, and $\alpha = 0.1$, their efficiencies become 1. DMUs 2, 4, 5, 6, 7, 9, 10, 12, 14, 20, and 25 are efficient in all levels of errors. It means these DMUs have excellent performance in different error levels

Given different α values, Table 4 shows the TE of supply chains using Expression (37). Taking into account Expression (37), the efficiency of the entire network is calculated. Note that in Expression (37), the network is not evaluated as a black box and interactions among stages are considered. As is seen, the higher α , the higher efficiency of DMUs. In Table 4, the whole network efficiency is reported. DMUs 4, 6, 7, 12, and 14 are evaluated as efficient. However, DMUs 1, 2, 3, 5, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27 are inefficient. The efficiency values are increased by considering different error levels. Note that DMU 28 is inefficient in $\alpha = 0.02$ and $\alpha = 0.04$ and is efficient in $\alpha = 0.06$, $\alpha = 0.08$, and $\alpha = 0.1$.

By comparing Tables 2, 3, and 4, we find out that DMUs 4, 6, 7, 12, and 14 are efficient in the two stages and entire network. As is seen in Table 4, the total efficient supply chains are those supply chains efficient in both stages. Now, improved factors are introduced. For the sake of brevity, the improved factors are introduced just for $\alpha = 0.1$. To this end, Table 5 reports the optimal values of decision variables associated with the inputs and outputs of suppliers given $\alpha = 0.1$. Note that the optimal values for efficient DMUs are zero.



Table 3 The stochastic efficiency of hospitals given different α values

DMUs	The stochastic	efficiencies given d	ifferent α values		
	$\alpha = 0.02$	$\alpha = 0.04$	$\alpha = 0.06$	$\alpha = 0.08$	$\alpha = 0.1$
DMU1	0.2698326	0.2698581	0.269874	0.2698869	0.2698969
DMU2	1	1	1	1	1
DMU3	0.2606178	0.2606487	0.260669	0.2606837	0.2606959
DMU4	1	1	1	1	1
DMU5	1	1	1	1	1
DMU6	1	1	1	1	1
DMU7	1	1	1	1	1
DMU8	0.9999999	0.9999999	1	1	1
DMU9	1	1	1	1	1
DMU10	1	1	1	1	1
DMU11	0.2553692	0.2553936	0.255409	0.2554213	0.2554309
DMU12	1	1	1	1	1
DMU13	0.2422501	0.2422878	0.242312	0.2423306	0.2423461
DMU14	1	1	1	1	1
DMU15	0.1067912	0.1067985	0.106803	0.1068068	0.1068097
DMU16	0.9999999	1	1	1	1
DMU17	0.3428785	0.3429677	0.343025	0.3430686	0.3431037
DMU18	0.2589658	0.2589825	0.258993	0.2590014	0.259008
DMU19	0.339317	0.3394024	0.339457	0.339499	0.3395326
DMU20	1	1	1	1	1
DMU21	0.1922634	0.1922849	0.192299	0.1923092	0.1923176

Table 3 (continued)

DMUs	The stochastic	efficiencies given d	ifferent α values		
	$\alpha = 0.02$	$\alpha = 0.04$	$\alpha = 0.06$	$\alpha = 0.08$	$\alpha = 0.1$
DMU22	0.1871395	0.1871595	0.187172	0.1871821	0.1871899
DMU23	0.1358884	0.1358939	0.135898	0.1359002	0.1359024
DMU24	0.2328609	0.2329552	0.233016	0.2330621	0.2331002
DMU25	1	1	1	1	1
DMU26	0.0662731	0.0662757	0.0662774	0.0662786	0.0662797
DMU27	0.4715435	0.4718461	0.47204	0.4721888	0.4723081
DMU28	0.9999999	0.9999999	1	1	1



Table 4 The stochastic TE of supply chains given different α values

DMUs	The stochastic T	E given different α	values		
	$\alpha = 0.02$	$\alpha = 0.04$	$\alpha = 0.06$	$\alpha = 0.08$	$\alpha = 0.1$
DMU1	0.23261388	0.23269756	0.23275109	0.2327921	0.232825
DMU2	0.589897	0.590586	0.590782	0.5913647	0.591636
DMU3	0.2606178	0.2606487	0.2606685	0.2606837	0.260696
DMU4	1	1	1	1	1
DMU5	0.37022	0.3702691	0.3702981	0.3703246	0.370344
DMU6	1	1	1	1	1
DMU7	1	1	1	1	1
DMU8	0.58717107	0.58729847	0.58734207	0.5874426	0.587493
DMU9	0.3373431	0.3373713	0.3374013	0.3374031	0.337414
DMU10	0.5973496	0.5974759	0.597568	0.5976188	0.597669
DMU11	0.2553692	0.2553936	0.2554092	0.2554213	0.255431
DMU12	1	1	1	1	1
DMU13	0.2422501	0.2422878	0.242312	0.2423306	0.242346
DMU14	1	1	1	1	1
DMU15	0.09005362	0.09006706	0.09007381	0.0900823	0.090088
DMU16	0.49415198	0.4944047	0.4945641	0.4946903	0.49479
DMU17	0.3428785	0.3429677	0.3430247	0.3430686	0.343104
DMU18	0.2589658	0.2589825	0.2589932	0.2590014	0.259008
DMU19	0.339317	0.3394024	0.339457	0.339499	0.339533
DMU20	0.4650577	0.4651244	0.4651564	0.4651999	0.465226
DMU21	0.1922634	0.1922849	0.1922986	0.1923092	0.192318

Table 4 (continued)

DMUs	The stochastic T	Έ given different α	values		
	$\alpha = 0.02$	$\alpha = 0.04$	$\alpha = 0.06$	$\alpha = 0.08$	$\alpha = 0.1$
DMU22	0.1871395	0.1871595	0.1871722	0.1871821	0.18719
DMU23	0.11063438	0.11064883	0.11066023	0.1106652	0.110671
DMU24	0.2328609	0.2329552	0.2330162	0.2330621	0.2331
DMU25	0.4037529	0.4038452	0.4038785	0.4039498	0.403986
DMU26	0.06196817	0.06197396	0.06197654	0.0619805	0.061983
DMU27	0.4715435	0.4718461	0.4720397	0.4721888	0.472308
DMU28	0.9999999	0.9999999	1	1	1



Table 5 The optimal values of the supplier decision variables

DMUs	β_1^{*1x}	β_2^{*1x}	β_3^{*1x}	β_4^{*1x}	$\dot{\tau}_1^{*1z}$	τ_2^{*1z}
DMU1	0.106	0.382	0.102	0.000	0.000	0.000
DMU2	0.000	0.573	0.036	0.000	0.081	0.000
DMU3	0.000	0.000	0.000	0.000	0.000	0.000
DMU4	0.000	0.000	0.000	0.000	0.000	0.000
DMU5	0.595	0.286	0.129	0.274	0.000	0.371
DMU6	0.000	0.000	0.000	0.000	0.000	0.000
DMU7	0.000	0.000	0.000	0.000	0.000	0.000
DMU8	0.196	0.453	0.006	0.000	0.000	0.044
DMU9	0.636	0.386	0.143	0.489	0.000	0.302
DMU10	0.000	0.118	0.000	0.158	0.000	0.325
DMU11	0.000	0.000	0.000	0.000	0.000	0.000
DMU12	0.000	0.000	0.000	0.000	0.000	0.000
DMU13	0.000	0.000	0.000	0.000	0.000	0.000
DMU14	0.000	0.000	0.000	0.000	0.000	0.000
DMU15	0.247	0.454	0.167	0.000	0.185	0.622
DMU16	0.039	0.078	0.117	0.003	0.784	0.000
DMU17	0.000	0.000	0.000	0.000	0.000	0.000
DMU18	0.000	0.000	0.000	0.000	0.000	0.000
DMU19	0.000	0.000	0.000	0.000	0.000	0.000
DMU20	0.335	0.240	0.000	0.129	0.000	0.423
DMU21	0.000	0.000	0.000	0.000	0.000	0.000
DMU22	0.000	0.000	0.000	0.000	0.000	0.000
DMU23	0.162	0.509	0.002	0.000	0.267	0.741
DMU24	0.000	0.000	0.000	0.000	0.000	0.000
DMU25	0.000	0.648	0.000	0.077	0.480	0.260
DMU26	0.035	0.067	0.592	0.319	0.030	0.000
DMU27	0.000	0.000	0.000	0.000	0.000	0.000
DMU28	0.000	0.000	0.000	0.000	0.000	0.000

Given $\alpha = 0.1$, Table 6 depicts the improved supplier factors. For inefficient DMUs, the inputs are reduced and the outputs are increased.

According to the initial inputs and outputs of the first stage in $\alpha=0.1$, and the improved data presented in Table 6, it can be said that the sum of inputs of DMUs is improved by an average of 0.94. Also, the total outputs of the first stage are improved by an average of 1.02. Given $\alpha=0.1$, Table 7 reports the optimal values of decision variables associated with the inputs and outputs of hospitals.

Given $\alpha = 0.1$, Table 8 depicts the improved hospital factors of. For inefficient DMUs, the inputs are reduced and the outputs are increased.

According to the initial inputs and outputs of the first stage in $\alpha = 0.1$ and the improved data presented in Table 8, it can be said that the sum of inputs of DMUs is improved by an average of 0.93. It can also be said that according to the initial inputs and outputs of the first



Table 6 The improved supplier factors

DMUs	Improved factors					
	\widehat{x}_1^{1x}	\widehat{x}_2^{1x}	\widehat{x}_3^{1x}	\widehat{x}_4^{1x}	\widehat{z}_1^{1z}	\widehat{z}_{2}^{1z}
DMU1	4,965,322,794.00	3.86%	224,637,655.82	1,890,000,000.00	233,270.00	9.20
DMU2	3,293,000,000.00	2.43%	172,593,039.13	1,113,000,000.00	160,815.00	5.56
DMU3	4,976,000,000.00	3.00%	152,130,000.00	1,452,000,000.00	186,453.00	9.40
DMU4	1,537,000,000.00	8.00%	74,935,000.00	612,735,000.00	62,590.00	4.92
DMU5	2,633,213,835.60	7.00%	107,859,664.27	979,263,670.38	151,815.00	7.96
DMU6	6,158,000,000.00	7.00%	212,650,000.00	2,527,000,000.00	255,740.00	11.54
DMU7	3,525,000,000.00	5.00%	135,412,000.00	1,255,000,000.00	175,153.00	9.23
DMU8	2,700,496,091.20	6.92%	110,304,627.84	952,580,000.00	153,625.00	7.88
DMU9	2,641,234,978.00	6.30%	118,080,972.96	636,794,678.26	148,755.00	7.20
DMU10	3,159,000,000.00	6.41%	140,875,000.00	972,651,868.68	169,452.00	8.93
DMU11	5,489,000,000.00	4.00%	315,260,000.00	2,350,000,000.00	247,390.00	9.45
DMU12	4,268,000,000.00	3.00%	137,582,000.00	1,273,000,000.00	147,439.00	6.79
DMU13	5,781,000,000.00	9.00%	294,500,000.00	2,754,000,000.00	259,716.00	8.48
DMU14	2,189,000,000.00	7.00%	99,156,000.00	901,270,000.00	137,411.00	7.86
DMU15	3,681,058,700.80	5.82%	190,191,426.47	1,183,000,000.00	190,840.00	11.66
DMU16	5,894,382,870.25	4.77%	223,314,617.82	2,375,980,399.20	253,986.00	9.83
DMU17	3,281,000,000.00	7.00%	120,552,000.00	1,093,000,000.00	172,820.00	8.07
DMU18	3,725,000,000.00	6.00%	198,340,000.00	1,412,000,000.00	195,473.00	12.91
DMU19	5,568,000,000.00	2.00%	236,520,000.00	2,189,000,000.00	251,815.00	7.69
DMU20	3,492,053,024.60	5.04%	137,781,000.00	1,057,812,726.38	173,520.00	8.65
DMU21	5,172,000,000.00	11.00%	255,728,000.00	1,974,000,000.00	246,826.00	9.76
DMU22	3,529,000,000.00	7.00%	165,782,000.00	1,729,000,000.00	192,150.00	7.80
DMU23	3,706,778,423.60	5.93%	194,959,997.66	1,317,000,000.00	193,551.00	12.39
DMU24	2,366,000,000.00	6.00%	114,870,000.00	1,260,000,000.00	146,750.00	6.53
DMU25	5,082,000,000.00	3.05%	226,451,019.45	1,984,098,656.22	236,957.00	9.08
DMU26	2,705,576,623.41	6.66%	132,512,860.40	1,073,035,059.27	156,938.00	9.57
DMU27	3,482,000,000.00	5.00%	153,265,000.00	145,100,000.00	169,845.00	5.94
DMU28	3,152,000,000.00	2.00%	175,359,000.00	1,192,000,000.00	157,190.00	5.05

stage in $\alpha = 0.1$, and the improved data presented in Table 8, the sum of absolute value of the outputs of DMUs is improved by an average of 1.83.

4.2 Managerial implications

The proposed method provides different implications for healthcare SC managers and decision makers. Healthcare SC efficiency in response to pandemics such as COVID-19 and SARS can be broken down into SC stages, and our use of the network RDM method can then enable managers to detect and trace inefficient resources. Thus, healthcare SC managers and decision makers can identify bottlenecks and take remedial measures. Another feature



0.72610 0.60953 0.00000.0 0.0000.0 0.0000.0 0.0000.0 0.0000.0 0.47700 0.00000 0.69964 0.0000.0 0.0000.0).68662 7.70477 0.0000.0 0.0000.0 0.0000.0 0.70744 0.56083 0.85371 3.40694 \dot{y}_2^{*2z} 0.0000.0).48513 0.0000.0 0.0000.0 0.38225 0.00000 0.03570 00000 00000 0.0000.0 0.0000.0 0.0000 0.435690.04875 0.26079 .43389 00000 1.57911 γ_1^{*2z}).18*6*7¢ 0.00000 0.30542 0.0000.0 0.00000 0.0000.0 0.0000.0 0.0000.0 0.0000.0 0.000170.0000.00.07062 0.08672 0.09728 0.09833 0.00027 00000.0 0.0000.0 0.02427 0.0000.0 δ_3*2y 0.03000 0.0000.0 0.0000.0 0.0000.0 0.0000.0 0.0000.0 0.00000 0.0000.0 0.0000.0 0.03000 0.10000 000000 00000.0 0.03000 0.0000.0 0.0000 0.0000 δ_2^{*2y} 5.80000 0.00000 .02740 78767.0 0.00000 0.00000 0.00000 0.00000 0.00000 0.24800 0.00000 0.72941 0.00000 0.52336 0.00000 00000 0.373740.29771 δ_1^{*2y} 0.37079 0.35000 0.0000.0 0.40310 0.0000.0 0.11864 0.0000.0 00000.0).61806 000000 0.00000 0.0000.0 0.0000.0 0.0000.0 0.0000.0 000000 0.14000 00000. 00000.0 322 .51471 β_5^{*2x} 0.00000 0.111143 0.00000 0.06300 0.00000 00000. 0.00000 0.00000 0.00000 0.00000 0.00000 0.13793 0.0000.0 0.19693 0.02390 0.00038 0.21470 000000).4030437737 β_4^{*2x} The optimal values of hospital decision variables of 0.30112 0.23418 0.00000 0.0000.0 0.0000.0 0.0000.0 0.00000 0.0000.0 0.00000 0.0000.0 0.12842 0.26422 0.24280 00000 50804 0.11425 0.0000.0 0.0000.0 0.33491 β_3^{*2x} 0.47619 0.0000.0 0.47059 0.00000 00000.0 0.0000.0 0.0000.0 0.00000 0.53333 0.0000.0 0.38462 0.56250 000000 00000.0 0.400000.461540.0000.0 0.0000.0 0.0000 0.2222 β_2^{*2x} 36743 00000 00000.0 000000.0 0.0000.0 0.0000.00.0000.0 0.00000 0.167460.0000.0 0.089700.0000 0.586840.0000.0 0.157960.52429 00000.0 .63615 0.20941 β_1^{*2x} 2MU12 DMU13 DMU14 DMU15 DMU16 DMU17 DMU18 DMU19 DMU22 DMU10 OMU20 DMU11 **DMUs** SMU8 9UMC 9MMC 2MU2 SMU3 MU4 SMU5 2MU7 1UMC



Table 7 (continued)	tinued)									
DMUs	β_1^{*2x}	β_2^{*2x}	β_3*2x	β_4^{*2x}	β_5^{*2x}	δ_1^{*2y}	δ ₂ *2y	δ_3*2y	γ_1^{*2z}	\dot{r}_2^{*2z}
DMU23	0.64523	0.42857	0.19852	0.12504	0.58915	3.43590	0.00000	0.14989	0.00180	0.78412
DMU24	0.09791	0.00000	0.21724	0.21987	0.39640	1.90909	0.00000	0.05318	0.00327	0.39305
DMU25	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000
DMU26	0.53231	0.38462	0.36583	0.25235	0.57718	11.23077	0.00000	0.00155	0.00292	0.74005
DMU27	0.00954	0.22222	0.15109	0.06248	0.47619	0.00000	0.00000	0.10596	0.08036	0.00942
DMU28	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000	0.00000



11.54 6.19 4.92 5.04 9.23 7.65 4.72 7.02 6.10 6.79 69.9 7.86 6.19 9.83 5.92 5.53 222 52,138.00 63,320.00 62,590.00 51,815.00 255,740.00 75,153.00 53,625.00 48,755.00 69,452.00 47,439.00 84,364.00 37,411.00 71,218.00 233,150.00 67,446.00 60,819.00 69,711.00 73,520.00 62,875.00 66,874.01 272 - 571,869,000.00 ,457,300,640.65 ,331,502,384.60 ,244,443,335.76 2,901,085,032.49 ,196,000,000.00 2,486,000,000.00 ,088,000,000,000 2,251,130,574.90 ,263,000,000.00 ,720,000,000.00 ,309,684,397.38 ,440,194,446.01 3,726,000,000.00 ,476,931,261.07 769,527,000.00 25,000,000.00 12,960,000.00 58,000,000.00 0000000000000 350 3795.00 2925.00 3795.00 3219.00 3815.00 3612.00 4806.00 3795.00 3997.00 4806.00 3612.00 1806.00 3745.00 493.00 3012.00 3496.00 3891.00 4158.00 3493.00 2865.00 252 85.00 95.00 58.00 267.00 117.00 00.69 286.00 101.00 153.00 139.00 92.00 54.00 263.00 406.00 237.00 235.00 94.00 218.00 25° 42.00 48.00 73.00 70.00 48.00 39.00 230.00 39.00 4.00 25.00 31.00 218.00 43.00 05.00 30.00 25 3592.00 3948.00 3972.00 5269.00 3726.00 3152.00 3759.00 3317.00 3996.00 5143.00 3950.00 3791.00 3805.00 3880.00 1173.00 3255.00 1260.00 x2x ,568,879,416.10 ,401,274,263.10 .622,746,536.70 ,416,334,502.90 ,141,000,000.00 5,460,261,372.80 3,152,000,000.00 5,226,000,000.00 ,826,000,000.00 5,682,000,000.00 4,925,000,000.00 5,780,000,000.00 5,294,000,000.00 ,527,695,764.80 5,358,000,000.00 5,958,684,008.00 5,026,000,000.00 5,625,607,321.00 369,000,000,000 5,597,000,000.00 x2x 35.00 13.00 65.00 44.00 37.00 51.00 40.00 41.00 37.00 15.00 34.00 13.00 59.00 37.00 252 Improved factors 20,710,126.17 39,135,000.00 14,235,976.39 56,425,000.00 95,168,000.00 21,105,000.00 05,759,000.00 83,525,000.00 99,282,000.00 19,943,433.30 18,525,000.00 44,601,248.25 07,520,000.00 22,209,002.30 35,505,000.00 19,569,767.08 08,116,309.03 36,642,508.60 39,895,000.00 35,536,000.00 x_1^2x DMU10 2MU12 DMU13 DMU14 DMU16 DMU17 MU18 MU15 2MU11 OMU20 DMU9 **DMUs** DMU8 **SMU3** MU4 **SMU5 MU6 SMU7** 2MU2 DMU1



Table 8 The improved hospital factors of

Table 8 (continued)

DMUs	Improved factors									
	\widehat{x}_1^{2x}	\widehat{x}_2^2x	\widehat{x}_3^{2x}	\widehat{x}_4^{2x}	\widehat{x}_5^{2x}	\widehat{y}_1^{2y}	\widetilde{y}_2^{2y}	$\widetilde{y_3}^{2y}$	$\frac{2}{z_1}$	$\frac{22^{2}}{2^{2}}$
DMU21	126,318,573.66	43.00	4,968,822,682.70	3057.00	162.00	224.00	3979.00	858,041,803.38	140,133.00	6.30
DMU22	116,867,781.96	41.00	4,728,537,760.00	2818.00	151.00	288.00	3495.00	718,267,200.61	129,296.00	5.92
DMU23	124,446,787.60	42.00	5,602,912,079.00	3951.00	149.00	381.00	3917.00	1,235,543,320.24	169,283.00	90.9
DMU24	134,144,911.15	39.00	5,209,087,761.20	3348.00	163.00	336.00	3625.00	536,219,572.20	146,475.00	5.82
DMU25	197,410,000.00	51.00	6,752,000,000.00	4885.00	230.00	186.00	6493.00	1,682,000,000.00	215,980.00	7.73
DMU26	130,835,955.33	42.00	5,293,576,893.50	3475.00	159.00	419.00	3875.00	906,166,675.22	153,464.00	5.98
DMU27	113,272,556.96	41.00	5,387,172,920.90	3769.00	140.00	115.00	3611.00	1,632,692,406.80	161,226.00	5.93
DMU28	149,240,000.00	38.00	5,510,000,000.00	3647.00	165.00	93.00	3458.00	465,250,000.00	157,190.00	5.05



of our proposed approach is its consideration of sustainability and resilience in measuring healthcare SC efficiency. Due to the pressures of social media, high competition, and public awareness, managers should integrate sustainability and resilience into their decisions. The proposed approach provides managers with a tool to deal with the sustainability and resilience issues in the face of disasters.

The proposed approach also deals with different types of data. These can help managers avoid making wrong the decisions leading to potential losses. Uncertainty in decision-making is another key challenge for managers in the face of disasters. To mitigate the risks, managers should not only apply appropriate approaches, they should also consider stochastic changes. The proposed method in this paper is a suitable tool for dealing with uncertainty. The obtained results show how the efficiency of healthcare SCs changes according to different Alpha values. This, in turn, assists healthcare managers and decision makers with better planning and resource allocation.

5 Conclusions and future research

The recent outbreak of Coronavirus resulting in an unprecedented crisis has negatively affected countries all over the world. Healthcare systems play a key role in facing such crises. Assessing the efficiency of healthcare SCs in disasters such as COVID-19 is critical. However, doing so, particularly in the face of uncertainty, is a major challenge for managers.

Jomthanachai et al. (2021) and Matin et al. (2022) measured supply chain resilience using DEA. Similarly, Kalantary and Farzipoor Saen (2022), Fathi and Farzipoor Saen (2021), Mohtashami et al. (2021), Dey et al. (2021), Malesios et al. (2020), and Wang et al. (2020) used DEA to measure supply chain sustainability. In all the cited papers, they used resilience and sustainability factors in DEA. Then, the efficiency scores obtained from DEA were interpreted as sustainability and resilience. In this paper, we proposed a new network RDM model to measure the sustainability and resilience of healthcare SCs. The developed model can deal with different types of data such as ratio, integer, stochastic, zero, and undesirable, simultaneously. Furthermore, we used the CCP approach to deal with stochastic data. Finally, we provided a case study to validate the proposed models. In sum, the study makes the following contributions: (1) proposing a novel network non-radial RDM model to evaluate the sustainability and resilience of healthcare SCs, (2) addressing different types of data such as ratio, integer, undesirable, stochastic, negative, and zero, simultaneously, (3) recommending how to enhance the inefficiency of healthcare SCs, (4) presenting a case study.

The results demonstrated how well our proposed method can evaluate the sustainability and resilience of healthcare SCs in view of different types of data. In addition, the results showed that under different conditions, the efficiency of healthcare SCs changes. Another contribution of this study is that it can support healthcare managers and decision makers in identifying and tracing inefficient resources. This allows them to then concentrate on bottlenecks and take remedial measures to improve the performance of sustainable-resilient healthcare SCs.

Owing to limitations in gathering data in this study, we identified 14 indicators for evaluating sustainable-resilient healthcare SCs. Nevertheless, other indicators that could be applied to assess sustainable-resilient healthcare SCs. Using the proposed method, we suggest researchers study translation invariance property in network DEA and measure the performance of healthcare SCs.



Acknowledgements The authors would like to express their appreciation to the four anonymous Reviewers for their constructive comments.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This article does not contain any studies with human participants performed by any of the authors.

Appendix

See Tables 9 and 10.



Table 9 Factors used to assess healthcare SC efficiency

Stages	Factors	Factor type	Data type	Notations	Sustainability/resilience dimension	Measurement units
Supplier	Raw material costs	Input	Real	x_1^1	Economic	Rial
	Rate of inferior raw material	Input	Ratio	x_{2}^{1}	Economic	Percentage
	Environmental costs	Input	Real	x_3^1	Environmental	Rial
	Personnel costs	Input	Real	x_{4}^{1}	Economic	Rial
	Number of produced kits	Intermediate	Integer	21	Economic	Number
	Average inventory	Intermediate	Stochastic	22	Resilience	Number of days, which the available kits meet demands of hospitals
Hospital	Employees' health and safety costs	External input	Real	x_1^2	Social	Rial
	Number of personnel	External input	Integer	x_{2}^{2}	Economic	Number
	Personnel costs	External input	Real	x_{3}^{2}	Economic	Rial
	Number of patients	External input	Integer	x_{4}^{2}	Economic	Number
	Number of beds	External input	Integer	x2 5	Economic	Number
	Number of errors in diagnosing COVID-19	Undesirable output	Integer	y_1^2	Economic	Number
	Number of discharged patients	Desirable output	Integer	322	Есопотіс	Number
	Profit	Desirable output	Negative, zero, and positive	332	Есопотіс	Rial



Fable 10 The dataset

Variance of 0.0000487nventory 0.000487 0.0004870.000111 000014 0.0004520.000529 0.000623 0.000487 0.000666 0.000196 999000'(0.000273 0.00088 0.00017 0.00088 0.000111 000401 Average inventory (Days) 9.45 6.79 8.48 4.92 5.04 1.54 9.23 7.65 4.72 7.02 9.61 Intermediate measures produced kits Number of 51,815 169,452 247,390 47,439 233,270 86,453 55,740 175,153 53,625 48,755 259,716 137,411 175,240 233,150 72,820 62,590 Personnel costs ,093,000,000 ,890,000,000 1,113,000,000 1,452,000,000 612,735,000 2,527,000,000 ,255,000,000 952,580,000 ,108,000,000 1,128,000,000 2,350,000,000 1,273,000,000 2,754,000,000 901,270,000 ,183,000,000 2,382,000,000 ,412,000,000 1,294,000,000 Environmental 20,552,000 76,250,000 52,130,000 25,263,000 40,875,000 315,260,000 37,582,000 242,960,000 98,340,000 241,700,000 12,726,000 212,650,000 35,412,000 10,528,000 294,500,000 213,350,000 costs (Rial) 74,935,000 9,156,000 Rate of inferior raw (Percentage) naterial Division 1 (Suppliers) Raw material costs 5,372,000,000 3,293,000,000 4,976,000,000 2,985,000,000 4,574,000,000 3,159,000,000 5,489,000,000 4,268,000,000 4,385,000,000 6,072,000,000 3,281,000,000 3,725,000,000 1,537,000,000 3,525,000,000 5,781,000,000 2,189,000,000 4,245,000,000 6,158,000,000 Inputs Supply chains (DMQs) 12 13 14 15 91 10 Ξ

Springer

Supply chains (DMUs) Division I (Suppliers) Environmental costs Environmental costs Environmental costs Environmental costs Intermediate measures 19 \$.568,000,000 2 236,520,000 2,189,000,000 24,475,000,000 25,25,128,000 1,148,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 216,984 8,53,25,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 7,748,000,000 215,980 215,980 7,748,000,000 215,326,500 1,145,000,000 1,145,000,000 1	Table 10 (continued)	d)						
Raw material costs Rate of inferior raw (Rial) Environmental costs (Rial) Personnel costs (Rial) Number of produced kits 5,568,000,000 2 236,520,000 2,189,000,000 251,815 4,475,000,000 6 137,781,000 1,193,000,000 173,520 5,172,000,000 7 165,782,000 1,250,000,000 169,475 4,125,000,000 6 114,870,000 1,260,000,000 146,750 5,082,000,000 6 114,870,000 1,250,000,000 169,475 2,366,000,000 6 114,870,000 1,260,000,000 146,750 5,082,000,000 6 114,870,000 2,138,000,000 115,837,30 2,748,000,000 7 226,510,000 2,138,000,000 153,3730 3,482,000,000 7 216,180,000 1,507,000,000 169,845 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 6 175,359,000 1,192,000,000 157,190	Supply chains	Division 1 (Suppliers)				Intermediate meas	sures	
Raw material costs Rate of inferior raw material costs Environmental Rial Personnel costs Number of produced kits 5,568,000,000 2 236,520,000 2,189,000,000 251,815 4,475,000,000 6 137,781,000 1,193,000,000 246,826 5,172,000,000 1 255,728,000 1,974,000,000 246,826 3,529,000,000 7 165,782,000 1,274,000,000 192,150 4,125,000,000 6 114,870,000 1,260,000,000 169,475 2,366,000,000 5 226,510,000 2,138,000,000 153,730 3,482,000,000 7 16,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 6 175,359,000 1,57,190	(DMUs)	Inputs						
5,568,000,000 2 236,520,000 2,189,000,000 251,815 4,475,000,000 6 137,781,000 1,193,000,000 173,520 5,172,000,000 11 255,728,000 1,974,000,000 246,826 4,125,000,000 7 165,782,000 1,729,000,000 192,150 4,125,000,000 6 114,870,000 1,260,000,000 146,750 5,082,000,000 5 226,510,000 2,138,000,000 153,730 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 133,265,000 1,92,100 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190		Raw material costs (Rial)	Rate of inferior raw material (Percentage)	Environmental costs (Rial)	Personnel costs (Rial)	Number of produced kits	Average inventory (Days)	Variance of inventory
4,475,000,000 6 137,781,000 1,193,000,000 173,520 5,172,000,000 11 255,728,000 1,974,000,000 246,826 3,529,000,000 7 165,782,000 1,729,000,000 192,150 4,125,000,000 6 114,870,000 1,260,000,000 169,475 1 5,082,000,000 5 226,510,000 2,138,000,000 146,750 15,980 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190	19	5,568,000,000	2	236,520,000	2,189,000,000	251,815	69.7	0.000188
5,172,000,000 11 255,728,000 1,974,000,000 246,826 3,529,000,000 7 165,782,000 1,729,000,000 192,150 4,125,000,000 10 195,250,000 1,507,000,000 169,475 1 2,366,000,000 6 114,870,000 1,260,000,000 146,750 146,750 5,082,000,000 5 226,510,000 2,138,000,000 215,980 15,790 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 1,75,359,000 1,192,000,000 157,190	20	4,475,000,000	9	137,781,000	1,193,000,000	173,520	5.53	0.000001
3,529,000,000 7 165,782,000 1,729,000,000 192,150 4,125,000,000 10 195,250,000 1,317,000,000 169,475 2,366,000,000 6 114,870,000 1,260,000,000 146,750 5,082,000,000 5 226,510,000 2,138,000,000 215,980 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190	21	5,172,000,000	11	255,728,000	1,974,000,000	246,826	9.76	0.000402
4,125,000,000 10 195,250,000 1,317,000,000 169,475 2,366,000,000 6 114,870,000 1,260,000,000 146,750 5,082,000,000 5 226,510,000 2,138,000,000 215,980 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190	22	3,529,000,000	7	165,782,000	1,729,000,000	192,150	7.80	0.000402
2,366,000,000 6 114,870,000 1,260,000,000 146,750 5,082,000,000 5 226,510,000 2,138,000,000 215,980 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190	23	4,125,000,000	10	195,250,000	1,317,000,000	169,475	10.92	0.000658
5,082,000,000 5 226,510,000 2,138,000,000 215,980 2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 1,75,359,000 1,192,000,000 157,190	24	2,366,000,000	9	114,870,000	1,260,000,000	146,750	6.53	0.000256
2,748,000,000 7 216,180,000 1,507,000,000 153,730 3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190	25	5,082,000,000	5	226,510,000	2,138,000,000	215,980	7.73	0.000231
3,482,000,000 5 153,265,000 1,451,000,000 169,845 3,152,000,000 2 175,359,000 1,192,000,000 157,190	26	2,748,000,000	7	216,180,000	1,507,000,000	153,730	9.57	0.000444
3,152,000,000 2 175,359,000 1,192,000,000 157,190	27	3,482,000,000	5	153,265,000	1,451,000,000	169,845	5.94	0.00088
	28	3,152,000,000	2	175,359,000	1,192,000,000	157,190	5.05	0.000667



Table 10 (continued)

Supply	Division 2 (Hospitals)	als)						
chains (DMUs)	External inputs					Outputs		
	Employees' health and safety costs (Rials)	Number of personnel	Personnel costs (Rial)	Number of patients	Number of beds	Number of errors in diagnosing COVID-19	Number of discharged patients	Profit (Rials)
1	120,850,000	53	6,255,000,000	4,573	185	149	3,742	2,900,000,000
2	89,135,000	39	5,141,000,000	3,619	112	98	2,925	1,196,000,000
3	147,816,000	47	5,758,000,000	4,062	146	192	3,697	1,475,000,000
4	56,425,000	35	3,152,000,000	1,173	96	117	1,493	0
5	95,168,000	43	5,226,000,000	3,255	105	169	3,012	958,000,000
9	121,105,000	65	7,826,000,000	5269	230	286	4,158	2,486,000,000
7	105,759,000	4	5,682,000,000	3,726	139	101	3,493	1,088,000,000
&	83,525,000	37	4,925,000,000	3,152	144	153	2,865	769,527,000
6	135,536,000	51	5,780,000,000	3,759	125	139	3,496	- 571,869,000



Supply	Division 2 (Hospitals)	als)						
chains (DMUs)	External inputs					Outputs		
	Employees' health and safety costs (Rials)	Number of personnel	Personnel costs (Rial)	Number of patients	Number of beds	Number of errors in diagnosing COVID-19	Number of discharged patients	Profit (Rials)
10	99,282,000	40	5,294,000,000	3,592	142	85	3,219	825,000,000
11	132,720,000	49	6,724,000,000	4,392	176	161	3,815	2,250,000,000
12	118,525,000	37	5,358,000,000	3,972	131	154	3,612	1,263,000,000
13	153,290,000	55	7,168,000,000	5,017	225	201	4,752	905,000,000
14	107,520,000	34	5,026,000,000	3,317	170	195	3,795	112,960,000
15	215,647,000	51	6,382,000,000	4,350	155	261	3,997	- 1,920,000,000
16	135,505,000	59	7,369,000,000	5,143	218	237	4,806	2,720,000,000
17	131,415,000	47	5,925,000,000	4,018	143	179	3,891	605,450,000
18	165,086,000	50	6,209,000,000	3,792	130	155	3,512	438,235,000
19	157,890,000	4	6,415,000,000	4,615	217	141	4,417	1,259,000,000
20	139,895,000	37	5,597,000,000	4,182	185	218	3.745	8,726,000,000



Table 10 (continued)

Table 10 (continued)

Supply	Division 2 (Hospitals)	uls)						
chains (DMUs)	External inputs					Outputs		
	Employees' health and safety costs (Rials)	Number of personnel	Personnel costs (Rial)	Number of patients	Number of beds	Number of errors in diagnosing COVID-19	Number of discharged patients	Profit (Rials)
21	248,520,000	49	6,845,000,000	4,329	232	187	3,979	0
22	213,205,000	43	5,728,000,000	3,815	240	213	3,495	718,255,000
23	248,160,000	48	6,210,000,000	4,348	225	247	3,917	- 85,170,000
24	142,580,000	39	5,780,000,000	3,961	207	231	3,625	76,250,000
25	197,410,000	51	6,752,000,000	4,885	230	186	6,493	1,682,000,000



Supply	Division 2 (Hospitals)	als)						
(DMUs)	External inputs					Outputs		
	Employees' health and safety costs (Rials)	Number of personnel	Personnel costs (Rial)	Number of patients	Number of beds	Number of errors in diagnosing COVID-19	Number of discharged patients	Profit (Rials)
26	215,527,000	47	6,529,000,000	4,252	245	273	3,875	894,000,000
27	113,820,000	43	5,785,000,000	3,942	180	115	3,611	792,010,000
28	149,240,000	38	5,510,000,000	3,647	165	93	3,458	465,250,000



Table 10 (continued)

References

- Allahyar, M., & Rostamy-Malkhalifeh, M. (2015). Negative data in data envelopment analysis: Efficiency analysis and estimating returns to scale. Computers & Industrial Engineering, 82, 78–81.
- Al-Saa'da, R. J., Taleb, Y. K. A., Al Abdallat, M. E., Al-Mahasneh, R. A. A., Nimer, N. A., & Al-Weshah, G. A. (2013). Supply chain management and its effect on health care service quality: Quantitative evidence from Jordanian private hospitals. *Journal of Management and Strategy*, 4(2), 42.
- Ayanso, A., & Mokaya, B. (2013). Efficiency evaluation in search advertising. *Decision Sciences*, 44(5), 877–913.
- Azadi, M., & Farzipoor Saen, R. (2011). A new chance-constrained data envelopment analysis for selecting third-party reverse logistics providers in the existence of dual-role factors. Expert Systems with Applications, 38(10), 12231–12236.
- Azadi, M., & Farzipoor Saen, R. (2014). Developing a new theory of integer-valued data envelopment analysis for supplier selection in the presence of stochastic data. *International Journal of Information Systems and Supply Chain Management*, 7(3), 80–103.
- Azadi, M., Shabani, A., Khodakarami, M., & Farzipoor Saen, R. F. (2014). Planning in feasible region by two-stage target-setting DEA methods: An application in green supply chain management of public transportation service providers. *Transportation Research Part e: Logistics and Transportation Review*, 70, 324–338.
- Banker, R. D., Charnes, A., & Cooper, W. W. (1984). Some models for estimating technical and scale inefficiencies in data envelopment analysis. *Management Science*, 30(9), 1078–1092.
- Besiou, M., Pedraza-Martinez, A. J., & Van Wassenhove, L. N. (2018). OR applied to humanitarian operations. European Journal of Operational Research, 269(2), 397–405.
- Charnes, A., Cooper, W. W., Golany, B., Seiford, L., & Stutz, J. (1985). Foundations of data envelopment analysis for Pareto-Koopmans efficient empirical productions functions. *Journal of Econometrics*, 30(1–2), 91–107.
- Charnes, A., Cooper, W. W., & Rhodes, E. (1978). Measuring the efficiency of decision making units. *European Journal of Operational Research*, 2(6), 429–444.
- Chen, C.-M., Du, J., Huo, J., & Zhu, J. (2012). Undesirable factors in integer-valued DEA: Evaluating the operational efficiencies of city bus systems considering safety records. *Decision Support Systems*, 54(1), 330–335.
- Chen, D. Q., Preston, D. S., & Xia, W. (2013). Enhancing hospital supply chain performance: A relational view and empirical test. *Journal of Operations Management*, 31(6), 391–408.
- Chen, Y., & Liang, L. (2011). Super-efficiency DEA in the presence of infeasibility: One model approach. European Journal of Operational Research, 213(1), 359–360.
- Cheng, G., Zervopoulos, P., & Qian, Z. (2013). A variant of radial measure capable of dealing with negative inputs and outputs in data envelopment analysis. *European Journal of Operational Research*, 225(1), 100–105.
- Chorfi, Z., Berrado, A., & Benabbou, L. (2019). An integrated DEA-based approach for evaluating and sizing health care supply chains. *Journal of Modelling in Management*, 15(1), 201–231.
- Dey, P. K., Yang, G.-L., Malesios, C., De, D., & Evangelinos, K. (2021). Performance management of supply chain sustainability in small and medium-sized enterprises using a combined structural equation modelling and data envelopment analysis. *Computational Economics*, 58(3), 573–613.
- Dolinskaya, I., Besiou, M., & Guerrero-Garcia, S. (2018). Humanitarian medical supply chain in disaster response. *Journal of Humanitarian Logistics and Supply Chain Management*, 8(2), 199–226.
- Elluru, S., Gupta, H., Kaur, H., & Singh, S. P. (2019). Proactive and reactive models for disaster resilient supply chain. Annals of Operations Research, 283(1), 199–224.
- Emrouznejad, A., & Amin, G. R. (2009). DEA models for ratio data: Convexity consideration. *Applied Mathematical Modelling*, 33(1), 486–498.
- Emrouznejad, A., Anouze, A. L., & Thanassoulis, E. (2010). A semi-oriented radial measure for measuring the efficiency of decision making units with negative data, using DEA. European Journal of Operational Research, 200(1), 297–304.
- Emrouznejad, A., & Yang, G.-L. (2018). A survey and analysis of the first 40 years of scholarly literature in DEA: 1978–2016. *Socio-Economic Planning Sciences*, 61, 4–8.
- Färe, R., & Grosskopf, S. (1996). Productivity and intermediate products: A frontier approach. *Economics Letters*, 50(1), 65–70.
- Fathi, A., & Farzipoor Saen, R. (2021). Assessing sustainability of supply chains by fuzzy Malmquist network data envelopment analysis: Incorporating double frontier and common set of weights. Applied Soft Computing, 113, 107923.



- Gerami, J., Kiani Mavi, R., Farzipoor Saen, R., & Kiani Mavi, N. (2020). 'A novel network DEA-R model for evaluating hospital services supply chain performance. *Annals of Operations Research*. https://doi.org/ 10.1007/s10479-020-03755-w
- Göleç, A., & Karadeniz, G. (2020). Performance analysis of healthcare supply chain management with competency-based operation evaluation. Computers & Industrial Engineering, 146, 106546.
- Goodarzian, F., Ghasemi, P., Gunasekaren, A., Taleizadeh, A. A., & Abraham, A. (2021). 'A sustainable-resilience healthcare network for handling COVID-19 pandemic. *Annals of Operations Research*. https://doi.org/10.1007/s10479-021-04238-2
- Govindan, K., Mina, H., & Alavi, B. (2020). A decision support system for demand management in healthcare supply chains considering the epidemic outbreaks: A case study of coronavirus disease 2019 (COVID-19). Transportation Research Part e: Logistics and Transportation Review, 138, 101967.
- Hatami-Marbini, A., & Toloo, M. (2019). Data envelopment analysis models with ratio data: A revisit. Computers & Industrial Engineering, 133, 331–338.
- Henriques, I. C., Sobreiro, V. A., Kimura, H., & Mariano, E. B. (2020). Two-stage DEA in banks: Terminological controversies and future directions. Expert Systems with Applications, 161, 113632.
- Hollingsworth, B., & Smith, P. (2003). Use of ratios in data envelopment analysis. *Applied Economics Letters*, 10(11), 733–735.
- Hoyos, M. C., Morales, R. S., & Akhavan-Tabatabaei, R. (2015). OR models with stochastic components in disaster operations management: A literature survey. Computers & Industrial Engineering, 82, 183–197.
- Izadikhah, M., Azadi, E., Azadi, M., Farzipoor Saen, R. F. & Toloo, M. (2020). Developing a new chance constrained NDEA model to measure performance of sustainable supply chains. *Annals of Operations Research*, pp. 1–29
- Izadikhah, M., Azadi, M., Shokri Kahi, V., & Farzipoor Saen, R. (2019). Developing a new chance constrained NDEA model to measure the performance of humanitarian supply chains. *International Journal of Production Research*, 57(3), 662–682.
- Izadikhah, M., & Farzipoor Saen, R. F. (2016). Evaluating sustainability of supply chains by two-stage range directional measure in the presence of negative data. *Transportation Research Part d: Transport and Environment, 49*, 110–126.
- Jola-Sanchez, A. F., Pedraza-Martinez, A. J., Bretthauer, K. M., & Britto, R. A. (2016). Effect of armed conflicts on humanitarian operations: Total factor productivity and efficiency of rural hospitals. *Journal* of Operations Management, 45, 73–85.
- Jomthanachai, S., Wong, W. P., Soh, K. L., & Lim, C. P. (2021). A global trade supply chain vulnerability in COVID-19 pandemic: An assessment metric of risk and resilience-based efficiency of CoDEA method. *Research in Transportation Economics*, 93, 101166.
- Kalantary, M., & Farzipoor Saen, R. (2022). A novel approach to assess sustainability of supply chains. Management Decision, 60(1), 231–253.
- Kao, C., & Hwang, S.-N. (2010). Efficiency measurement for network systems: IT impact on firm performance. Decision Support Systems, 48(3), 437–446.
- Karmaker, C. L., Ahmed, T., Ahmed, S., Ali, S. M., Moktadir, M. A., & Kabir, G. (2020). Improving supply chain sustainability in the context of COVID-19 pandemic in an emerging economy: Exploring drivers using an integrated model. Sustainable Production and Consumption, 26, 411–427.
- Khoveyni, M., Eslami, R., Fukuyama, H., Yang, G.-L., & Sahoo, B. K. (2019). Integer data in DEA: Illustrating the drawbacks and recognizing congestion. *Computers & Industrial Engineering*, 135, 675–688.
- Khoveyni, M., Eslami, R., & Yang, G.-L. (2017). Negative data in DEA: Recognizing congestion and specifying the least and the most congested decision making units. *Computers & Operations Research*, 79, 39–48.
- Kordrostami, S., Amirteimoori, A., & Noveiri, M. J. S. (2019). Inputs and outputs classification in integer-valued data envelopment analysis. *Measurement*, 139, 317–325.
- Land, K. C., Lovell, C. K., & Thore, S. (1993). Chance-constrained data envelopment analysis. Managerial and Decision Economics, 14(6), 541–554.
- Lee, H.-S., & Zhu, J. (2012). Super-efficiency infeasibility and zero data in DEA. European Journal of Operational Research, 216(2), 429–433.
- Leite, H., Lindsay, C., & Kumar, M. (2020). COVID-19 outbreak: Implications on healthcare operations. *The TQM Journal*, 33(1), 247–256.
- Leksono, E. B., Suparno, S., & Vanany, I. (2019). Integration of a balanced scorecard, DEMATEL, and ANP for measuring the performance of a sustainable healthcare supply chain. *Sustainability*, 11(13), 3626.
- Lewis, H. F., & Sexton, T. R. (2004). Network DEA: Efficiency analysis of organizations with complex internal structure. Computers & Operations Research, 31(9), 1365–1410.
- Lin, R., & Chen, Z. (2018). Modified super-efficiency DEA models for solving infeasibility under non-negative data set. INFOR Information Systems and Operational Research, 56(3), 265–285.



- Lozano, S., & Villa, G. (2006). Data envelopment analysis of integer-valued inputs and outputs. *Computers & Operations Research*, 33(10), 3004–3014.
- Malesios, C., Dey, P. K., & Abdelaziz, F. B. (2020). Supply chain sustainability performance measurement of small and medium sized enterprises using structural equation modeling. *Annals of Operations Research*, 294(1–2), 623–653.
- Matin, R. K., Azadi, R., & Farzipoor Saen, R. (2022). Measuring the sustainability and resilience of blood supply chains. *Decision Support Systems*, 161, 113629.
- Matin, R. K., & Kuosmanen, T. (2009). Theory of integer-valued data envelopment analysis under alternative returns to scale axioms. Omega, 37(5), 988–995.
- Md Hamzah, N., Yu, M. M., & See, K. F. (2021). Assessing the efficiency of Malaysia health system in COVID-19 prevention and treatment response. *Health Care Management Science*, 24(2), 273–285.
- Min, H., Lee, C. C., & Joo, S. J. (2021). Assessing the efficiency of the Covid-19 control measures and public health policy in OECD countries from cultural perspectives. *Benchmarking: An International Journal*. https://doi.org/10.1108/BIJ-05-2021-0241
- Mirhedayatian, S. M., Azadi, M., & Saen, R. F. (2014). A novel network data envelopment analysis model for evaluating green supply chain management. *International Journal of Production Economics*, 147, 544–554.
- Mohtashami, Z., Bozorgi-Amiri, A., & Tavakkoli-Moghaddam, R. (2021). A two-stage multi-objective second generation biodiesel supply chain design considering social sustainability: A case study. *Energy*, 233, 121020.
- Nyaga, G. N., Young, G. J., & Zepeda, E. D. (2015). An analysis of the effects of intra-and interorganizational arrangements on hospital supply chain efficiency. *Journal of Business Logistics*, 36(4), 340–354.
- Olesen, O. B., & Petersen, N. (1995). Chance constrained efficiency evaluation. Management Science, 41(3), 442–457.
- Portela, M. S., Thanassoulis, E., & Simpson, G. (2004). Negative data in DEA: A directional distance approach applied to bank branches. *Journal of the Operational Research Society*, 55(10), 1111–1121.
- Rainisch, G., Undurraga, E. A., & Chowell, G. (2020). A dynamic modeling tool for estimating healthcare demand from the COVID19 epidemic and evaluating population-wide interventions. *International Journal of Infectious Diseases*, 96, 376–383.
- Ruan, J., Wang, X., & Shi, Y. (2014). A two-stage approach for medical supplies intermodal transportation in large-scale disaster responses. *International Journal of Environmental Research and Public Health*, 11(11), 11081–11109.
- Samavati, T., Badiezadeh, T., & Saen, R. F. (2020). Developing double frontier version of dynamic network DEA model: assessing sustainability of supply chains. *Decision Sciences.*, 51(3), 804–829.
- Sharmin, A., Rahman, M., Ahmed, S., Ali, S. M. (2021). Addressing critical success factors for improving concurrent emergency management: lessons learned from the COVID-19 pandemic. *Annals of Operations Research* pp. 1–35
- Supeekit, T., Somboonwiwat, T., & Kritchanchai, D. (2016). DEMATEL-modified ANP to evaluate internal hospital supply chain performance. *Computers & Industrial Engineering*, 102, 318–330.
- Tavana, M., Izadikhah, M., Di Caprio, D., & Farzipoor Saen, R. (2018). A new dynamic range directional measure for two-stage data envelopment analysis models with negative data. *Computers & Industrial Engineering*, 115, 427–448.
- Tavassoli, M., Farzipoor Saen, R., & Faramarzi, G. R. (2015). Developing network data envelopment analysis model for supply chain performance measurement in the presence of zero data. *Expert Systems*, 32(3), 381–391.
- Troutt, M. D., Gribbin, D. W., Shanker, M., & Zhang, A. (2000). Cost efficiency benchmarking for operational units with multiple cost drivers. *Decision Sciences*, 31(4), 813–832.
- Verma, S., & Gustafsson, A. (2020). Investigating the emerging COVID-19 research trends in the field of business and management: A bibliometric analysis approach. *Journal of Business Research*, 118, 253–261.
- Wang, H., Pan, C., Wang, Q., & Zhou, P. (2020). Assessing sustainability performance of global supply chains: An input-output modeling approach. *European Journal of Operational Research*, 285(1), 393–404.
- Wu, J., & Zhou, Z. (2015). A mixed-objective integer DEA model. Annals of Operations Research, 228(1), 81–95.
- Zahedi, A., Salehi-Amiri, A., Smith, N. R., & Hajiaghaei-Keshteli, M. (2021). Utilizing IoT to design a relief supply chain network for the SARS-COV-2 pandemic. *Applied Soft Computing*, 104, 107210.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Majid Azadi¹ · Zohreh Moghaddas² · Reza Farzipoor Saen³ · Angappa Gunasekaran⁴ · Sachin Kumar Mangla⁵ · Alessio Ishizaka⁶

Majid Azadi m.azadi@deakin.edu.au

Zohreh Moghaddas zmoghaddas@qiau.ac.ir

Reza Farzipoor Saen farzipour@yahoo.com

Angappa Gunasekaran aqg6076@psu.edu

Sachin Kumar Mangla sachinmangL@gmail.com

- Department of Information Systems and Business Analytics, Deakin Business School, Deakin University, Melbourne, VIC, Australia
- Department of Mathematics, Qazvin Branch, Islamic Azad University, Qazvin, Iran
- Department of Operations Management & Business Statistics, College of Economics and Political Science, Sultan Qaboos University, Muscat, Oman
- School of Business Administration, Penn State Harrisburg, Middletown, PA, USA
- Digital Circular Economy for Sustainbale Development Goals (DCE-SDG), Jindal Global Business School, O P Jindal Global University, Haryana, India
- NEOMA Business School, 1 rue du Maréchal Juin BP 215, 76130 Mont-Saint-Aignan, France

